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To my daughter Ulla
Strange fishes glide in the depths,
unfamiliar flowers glow on the shore;
I have seen red and yellow and all the other colours, –
but the gaudy gay sea is the most dangerous to look upon,
it makes one thirsty and wide-awake for waiting adventures:
what happened in the fairy-tale will happen also to me!
 
Edith Södergran: Strange Sea 
Dikter, 1916, translation David McDuff 
(with permission)
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Primary uveal melanoma is the most common intraocular malignant tumour in adults. 
It metastasises in more than half of patients, and even 35 years after the diagnosis of the 
primary tumour, metastatic uveal melanoma is the leading cause of death. However, no 
consensus exists regarding either screening or treatment of metastatic disease. The aims 
of this study are to provide a systematic review and meta-analysis of the current literature 
regarding the survival of actively treated patients with metastatic uveal melanoma; to 
describe a national cohort with metastatic uveal melanoma; and by means of this cohort, 
to analyse both the agreement of imaging modalities in diagnosis of metastatic disease and 
the stage-stratified survival of patients who received best supportive care (BSC) and active 
treatment. 
METHODS
Study I was a systematic review and meta-analysis of original, peer-reviewed articles 
published between January 1, 1980 and March 29, 2017, reporting individual-level survival 
in Kaplan-Meier plot or numerical form. The survival graphs were digitised, and individual 
survival times were pooled. The median overall survival (OS) was calculated by treatment 
modality, and modalities were compared by the log-rank test and Cox regression, adopting 
conventional chemotherapy (CHT) as a reference. 
For Studies II–IV, a nationwide cohort of patients was identified, whose metastases were 
diagnosed between January 1, 1999 and December 31, 2016 after the primary tumour had 
been managed in the Ocular Oncology Service, Helsinki University Hospital, which is a 
national referral centre. If a computed tomography (CT) or magnetic resonance imaging 
(MRI) was performed within 60 days of the upper abdominal ultrasonography (US), then 
the agreement of findings was studied regarding the presence and number of metastases 
(Study II). To study the survival of patients who received BSC (Study III) or active treatment 
(Study IV), they were assigned to stages IVa, IVb, and IVc, corresponding to predicted 
median OS of ≥12 months, <12–6 months, and <6 months, by using the Helsinki University 
Hospital Working Formulation (WF), previously validated by the European Ophthalmic 
Oncology Group (OOG). The primary endpoint was OS. It was compared with the Kaplan-
Meier product-limit method and Cox proportional hazards regression analysis against BSC 
and between active treatment modalities (Study IV).
The meta-analysis included 2,494 patients from 78 studies, and the median OS was 13 
months. Of the treatment modalities with >100 patients, the pooled median OS was 5–6 
months longer with surgery and IHP and 4 months shorter with CPI than with CHT, for 
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which the median OS was 11 months (P < 0.010, log-rank test). However, OS was subject to 
identifiable confounding factors related to the heterogeneity in the included studies. 
The nationwide cohort with metastatic uveal melanoma comprised 338 patients, of whom 
metastatic disease was diagnosed in 215 patients with US and CT/MRI within 60 days. The 
sensitivity of US in detecting metastases was 96% (95% confidence interval [CI], 92–98). 
Moreover, US detected metastases in 95% of the patients and agreed with a staging CT/
MRI on their presence in 89% of patients, showing at least the same number of lesions as 
CT/MRI in 72% of patients, and in nine patients, it detected metastases that CT initially 
missed for various reasons. 
In the nationwide cohort, 108 patients who were analysed received BSC and 216 active 
treatment. Of the patients who received BSC, 24%, 19%, and 55% represented WF stages 
IVa, IVb, and IVc, respectively. The median OS shortened with increasing stages, and 
calculated from the treatment decision (i.e. BSC), it was 12 months (95% CI, 9.4–21) for 
stage IVa, 5.7 months (95% CI, 0.7–11) for stage IVb, and 0.6 months (95% CI, 0.3–0.9) for 
stage IVc (P < 0.001, log-rank test for trend). 
Of the 216 patients who received active treatment, 66%, 17%, and 15% represented WF 
stages IVa, IVb, and IVc, respectively. The median OS also shortened with increasing stages, 
and calculated from treatment decision, it was 18 months (95% CI, 16–21) for stage IVa, 6.9 
months (95% CI, 4.8–9.7) for stage IVb, and 1.9 months (95% CI, 1.6–2.9) for stage IVc (P 
< 0.001, log-rank test for trend). In stage IVa, patients who received chemoimmunotherapy 
with interferon or interleukin (CIT) or local therapy, especially surgical resection, as their 
first-line treatment had a longer OS (18 and 27 months, respectively) than patients who 
received CHT (10 months) (P < 0.020). However, compared to BSC, OS after CIT in stage 
IVa was comparable (P > 0.99, corrected for multiple comparisons by stage), as was survival 
after selective internal radiation therapy (SIRT) (P = 0.58). Finally, we did not observe any 
convincing difference in OS relative to that after BSC in any comparison in stage-IVb or 
-IVc patients. 
MAIN CONCLUSIONS
The meta-analysis suggested no clinically significant difference by treatment modality, 
although for patients with solitary hepatic metastases, surgery might have been more 
effective than CHT. However, the studies reviewed were heterogeneous. In the nationwide 
cohort, hepatic US was a sensitive follow-up modality, supporting its continued use as the 
primary imaging method for this purpose. The median OS was comparable to that of BSC 
patients with main treatment modalities—except with CHT and surgery in stage IVa, the 
former being associated with shorter and the latter with longer survival. Surgical resection 
may be superior but is available only for a minority of patients. No current treatment that is 
available for most patients with metastatic uveal melanoma is likely to appreciably prolong 
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OS. Furthermore, validated staging systems and proper historical control groups are crucial 
for correct interpretation of the outcomes in non-randomised trials.
uveal melanoma; uveal neoplasms; melanoma; metastasis; treatment; best supportive care; 
chemotherapy; surgery; chemoimmunotherapy; immunotherapy; targeted therapy; selective 
internal radiation therapy; isolated hepatic perfusion; transarterial chemoembolisation; 





Suonikalvoston melanooma on yleisin aikuisten silmänsisäinen pahanlaatuinen 
kasvain. Yli puolet potilaista sairastuu levinneeseen tautiin, joka on yleisin kuolinsyy 
jopa 35 vuoden kuluttua emokasvaimen diagnoosista. Levinneen taudin seulomisesta 
tai sen hoidosta ei vallitse yhteisymmärrystä. Tavoitteeni oli selvittää systemoidun 
kirjallisuuskatsauksen ja meta-analyysin avulla levinnyttä suonikalvoston melanoomaa 
sairastavien aktiivisesti hoidettujen potilaiden elossaoloaika. Keräsin valtakunnallisen 
aineiston levinnyttä suonikalvoston melanoomaa sairastaneista potilaista ja tutkin sen 
avulla kuvantamismenetelmien yhtenevyyttä levinneen taudin diagnostiikassa sekä 
oireenmukaisesti ja aktiivisesti hoidettujen potilaiden elossaoloaikaa levinneisyysluokan 
mukaisesti. 
MENETELMÄT
Osatyö I oli systemoitu katsaus ja meta-analyysi vertaisarvioiduista artikkeleista, 
jotka julkaistiin 1.1.1980 ja 29.3.2017 välisenä aikana PubMedissa, ja jotka sisälsivät 
potilaskohtaista tietoa eloonjäämisestä joko Kaplan-Meier -kuvaajan tai lukujen 
muodossa. Digitoin kuvaajat ja yhdistin elossaoloajat. Laskin mediaani elossaoloajan eri 
hoitomuodoille ja vertasin niitä perinteiseen kemoterapiaan Kaplan-Meierin menetelmällä 
ja Coxin suhteellisten riskitiheyksien regressioanalyysilla. 
Osatyöt II–IV perustuivat valtakunnalliseen aineistoon potilaita, joiden levinnyt tauti oli 
todettu 1.1.1999 ja 31.12.2016 välisenä aikana, ja joiden emokasvain oli hoidettu Hyksin 
silmätautien klinikassa, johon suonikalvoston melanooman hoito on valtakunnallisesti 
keskitetty. Niiltä potilailta, joiden etäpesäkkeet oli havaittu kaikututkimuksella ja siitä 
60 päivän sisällä tehdyllä tietokonetomografia (TT)- tai magneettitutkimuksella (MRI), 
tarkastelin kuvantamislöydösten yhtenevyyttä siltä osin, oliko etäpesäkkeitä havaittu ja 
jos oli, niin kuinka monta. Elossaoloaikaa tutkin jakamalla potilaat kolmeen ryhmään 
Euroopan silmäkasvainryhmän monikeskustutkimuksen validoiman Helsinki University 
Hospital Working Formulationin perusteella. Levinneisyysluokat IVa, IVb ja IVc edustavat 
elinajan odotetta ≥12, <12–6 ja <6 kuukautta. Tutkimuksen ensisijainen päätetapahtuma 
oli kokonaiselossaoloaika, jota vertasin oireenmukaisen hoidon sekä eri hoitomuotojen 
jälkeiseen elossaoloaikaan Kaplan-Meierin menetelmällä ja Coxin suhteellisten 
riskitiheyksien regressioanalyysilla. 
TULOKSET
Meta-analyysiin löytyi 2494 potilasta 78 tutkimuksesta. Mediaani kokonaiselossaoloaika oli 
13 kk. Niistä hoitomuodoista, joita sai >100 potilasta, isoloitu maksaperfuusio ja kirurgia 
pidensivät elossaoloaikaa 5–6 kk ja tarkistuspisteen estäjät lyhensivät sitä 4 kk verrattuna 
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perinteiseen kemoterapiaan, jonka jälkeen mediaani kokonaiselossaoloaika oli 11 kk. Meta-
analyysiin sisältyvien julkaisujen heterogeenisyys paljasti tunnistettavissa olevia sekoittavia 
tekijöitä.
Valtakunnallinen aineisto koostui 338 potilaasta, joiden levinneistä taudeista 215 oli 
todettu kaikukuvauksella 60 päivän sisällä TT- tai MRI-tutkimuksesta. Kaikukuvauksen 
herkkyys havaita etäpesäke oli 96 % (95 % luottamusväli [LV], 92–98). Kaikukuvaus havaitsi 
etäpesäkkeet 95 %:lla potilaista ja oli 89 %:lla yhtenevä TT/MRI-tutkimuksen kanssa sen 
suhteen havaittiinko etäpesäkkeitä vai ei. Kaikukuvaus havaitsi 72 %:lla potilaista vähintään 
yhtä monta etäpesäkettä kuin TT/MRI, ja yhdeksällä potilaalla etäpesäkkeen, joka jäi 
TT-tutkimuksessa huomiotta. Tulokset tukevat kaikututkimuksen käytön jatkamista 
valtakunnallisena seulontamenetelmänä.
Koko aineistossa 108 potilasta sai oireenmukaista hoitoa. Heistä 24 % kuului 
levinneisyysluokkaan IVa, 19 % luokkaan IVb ja 55 % luokkaan IVc. Mediaani 
kokonaiselossaoloaika lyheni levinneisyysluokan mukaan ja oli 12 kk (95 % LV, 9.4–21) 
luokassa IVa, 5.7 kk (95 % LV, 0.7–11) luokassa IVb ja 0.6 kk (95 % LV, 0.3–0.9) luokassa 
IVc (P < 0.001, log-rank trenditesti). 
Kahdestasadastakuudestatoista potilaasta, jotka saivat aktiivista hoitoa, 66 % kuului 
levinneisyysluokkaan IVa, 17 % luokkaan IVb ja 15 % luokkaan IVc. Mediaani 
kokonaiselossaoloaika oli sitä lyhyempi mitä korkeampi luokka oli: 18 kk (95 % LV, 16–21) 
luokassa IVa, 6.9 kk (95 % LV, 4.8–9.7) luokassa IVb, ja 1.9 kk (95 % LV, 1.6–2.9) luokassa 
IVc (P < 0.001, log-rank trenditesti). Luokan IVa kokonaiselossaoloaika oli pitempi, jos 
maksaetäpesäkkeiden ensilinjan hoito oli kemoimmunoterapia tai paikallishoito, erityisesti 
kirurgia, kuin jos se oli perinteinen solunsalpaajahoito (18 kk, 27 kk ja 10 kk, P < 0.020). 
Kemoimmunoterapialla ja maksan radioembolisaatiolla saatiin oireenmukaiseen hoitoon 
verrattava kokonaiselossaoloaika (P > 0.99 ja P = 0.58, log-rank testi). Levinneisyysluokkien 
IVb ja IVc potilaat eivät vakuuttavasti hyötyneet mistään hoitomuodosta.
PÄÄTELMÄT
Meta-analyysissa totesin, ettei kokonaiselossaoloaika millään hoitomuodolla paitsi 
mahdollisesti etäpesäkkeiden kirurgisella poistolla poikennut perinteisellä kemoterapialla 
saavutetusta. Analysoidut tutkimukset olivat heterogeenisiä. Valtakunnallisen aineiston 
perusteella ylävatsan kaikututkimus oli herkkä menetelmä toteamaan maksaetäpesäkkeet. 
Mediaani kokonaiselossaoloaika oli verrattavissa oireenmukaisesti hoidettujen potilaiden 
elossaoloaikoihin aktiivisilla hoitomuodoilla paitsi perinteisellä solunsalpaajahoidolla 
ja kirurgialla levinneisyysluokassa IVa, jossa se oli ensin mainitulla lyhyempi ja viimeksi 
mainitulla pidempi. Todennäköisesti mikään nykyinen hoito paitsi kirurgia ei pidennä 
useimpien levinnyttä uveamelanoomaa sairastavien potilaiden elossaoloaikaa. Kirurginen 
poisto on kuitenkin harvoin mahdollinen, koska maksassa on yleensä useampia 
etäpesäkkeitä. Validoidun levinneisyysluokituksen ja asianmukaisten verrokkien 
käyttäminen on välttämätöntä hoitotutkimusten oikealle tulkinnalle.
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Uveal melanoma is the most common primary malignant intraocular tumour in adults, 
with a mean age-adjusted incidence of 6.6 per million in Europe (as calculated from [1]) 
and 5.1 per million in the United States [2]. Most of uveal melanomas affect Caucasians, but 
the incidence varies by age, ethnicity, and latitude from 0.1 to 8.6 per million [1,3,4], with 
the incidence being highest in Scandinavia and northern latitudes of North America [4]. 
Furthermore, more than half of uveal melanomas result in clinical metastases [2,5,6], and 
thereafter, historically, the median overall survival (OS) was less than 6 months at a time 
when mainly liver function tests (LFTs) and chest radiography were used for follow-up [6]. 
In 90% of the patients, the liver is the first site of metastasis, followed by the lungs, bone, 
skin, and lymph nodes [6-8]. The liver remains the only site of metastasis in half of patients 
[5,7,8]. At the time of diagnosis of the primary tumour, only 1–3% have metastases; thus, it 
is a more frequent finding to detect benign hepatic abnormalities and synchronous primary 
cancers [9,10]. 
However, there is no agreement on follow-up. Each referral centre has its preferred imaging 
modality and frequency for screening for metastases. The frequency of imaging varies 
depending on participation in ongoing trials and perceived risk of dissemination indicated 
by tumour histology and its genetic profile, with high-risk patients often surveilled 4- to 
6-monthly [11-15] based partly on the estimated tumour doubling times of metastases 
[16]. In Europe, hepatic ultrasonography (US) is widely used to screen for metastases, and 
computed tomography (CT) and magnetic resonance imaging (MRI) are scheduled if a 
suspicious new lesion is detected [17-20], although some large centres also prefer MRI for 
screening [11,21]. At some tertiary-referral centres in the United States, the follow-up is 
also done using MRI with a contrast agent for the liver and CT for the chest, abdomen, and 
pelvis [22]. US is used less frequently there because of its limitations in the obese [14], and 
fear of malpractice claims in the absence of practice guidelines also leads to a preference for 
surveillance with CT [23]. 
Given the small number of patients with metastatic uveal melanoma, few randomised 
controlled treatment trials have been conducted: hepatic intra-arterial (IA) versus 
intravenous (IV) fotemustine [24], selumetinib combined with dacarbazine versus placebo 
combined with dacarbazine [25], immunoembolisation versus bland embolisation [26], 
intrahepatic cisplatin with or without polyvinyl sponge [27], and a discontinuation trial 
with cabozantinib [28]. The largest one included 171 patients [24]. Retrospective cohort 
studies are frequent but often lack patient-level information about prognostic factors and 
specific treatments [29]. Patients who undergo surgery possibly have prolonged OS, but 
it necessitates an early detection of relatively few metastases [11]. In addition, new, more 
effective treatments for metastatic cutaneous melanoma [30,31] have not provided any 
survival benefit for patients with metastatic uveal melanoma [25], except possibly for 
those with loss-of-function variants in the methyl-CpG binding domain-4 (MBD4) gene; 
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however, their frequency among these patients is only 1% [32,33]. Unlike cutaneous 
melanoma, uveal melanoma rarely carries any mutation in B-Raf proto-oncogene (BRAF) 
[34,35]. Local treatments have been suggested to prolong survival [36-38], but no consensus 
exists on the treatment of metastatic uveal melanoma. 
The objective of this thesis is to assess OS through a meta-analysis of published, peer-
reviewed studies on metastatic uveal melanoma containing patient-level data. By means 
of a nationwide cohort, the aim is to evaluate the agreement of imaging modalities at the 
time of diagnosis of metastatic uveal melanoma to ascertain the most suitable method and 
to report stage-stratified OS, with a special interest in the survival of patients who received 





One half of patients with primary uveal melanoma develop metastases despite the relatively 
successful eradication—5–10% rate of local relapse—of the primary tumour without 
enucleating the eye [2,5]. A metastatic rate of 50% is reached in 10 years in studies using 
the Kaplan-Meier analysis and in 25 years if competing causes of death are taken into 
account [5]. Metastasis is most frequently observed within 2–5 years after the diagnosis of 
the primary tumour [6], and even after 35 years of follow-up, metastatic uveal melanoma 
is the most common cause of death (COD) for patients with primary uveal melanoma that 
was treated with enucleation—an approach that minimises the risk of local recurrence [5]. 
At the time of diagnosis of the primary tumour, only 1–3% of patients have metastases 
[9,10]. In a study of 4,070 patients with primary uveal melanoma, approximately 10% had a 
history of a reported malignancy before the diagnosis of the primary uveal melanoma [2]. 
Uveal melanoma disseminates hematogenously, and its propensity to home to the liver has 
been designated as one of the most unusual phenomena in tumour biology [39]. More than 
half of patients will develop their first metastasis in the liver—eventually 90% of patients 
have liver metastases—followed by the lungs, bone, skin, and lymph nodes [6,8,39-41].
The small number of metastases at the time of diagnosis and the fact that metastases 
from uveal melanoma are the most common COD, even after enucleation, indicate early 
subclinical metastasis in patients who have acquired the genetic events necessary for 
dissemination [5,16]. The mathematical background for the exponential growth of cells was 
published in 1956 [42]. In general, 30 doubling times are required for a single 10- m cell 
to grow to a 10-mm3 mass containing 1 billion cells [43]. There are at least two possible 
doubling time clones in uveal melanoma: one for the primary uveal melanoma and one 
for the metastasis [2,16]. In general, the doubling time of the primary tumour has been 
suggested to range from 154 to 511 days [44,45], and that of the metastasis from 30 to 80 
days [16]. 
Lead time bias refers to the phenomenon where early diagnosis of a disease makes it look 
like the patients would survive longer subsequently [46]. Lead time bias may result in a false 
impression of improved survival or treatment effect. It is consequently crucial that patients 
in trials are randomised or categorised according to a similar condition. Randomisation 
necessitates that the review for metastases has been constant. For categorisation, validated 
prognostic tools and staging systems are required [47].
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Since the 1970s, screening for metastatic uveal melanoma has been recommended [39]; 
however, the justification for surveillance has also been questioned because of a lack of 
evidence that current treatment modalities prolong OS [48-50]. Despite mounting evidence 
that local treatments for liver metastases improve OS, those treatments are often impossible 
because of a high metastatic burden, which makes an early diagnosis of the metastases 
necessary [11,19,37,51-53]. Nonetheless, in two studies with frequent 6-monthly MRI-
based screening, only 14% and 11% of patients were eligible for hepatic resection [11,54]. 
The psychological aspect of surveillance is a benefit that patients may appreciate [55], and 
uniform screening guidelines would improve patients’ eligibility for treatment trials and 
their comparability [18,56]. While attempts have been made, there is still no consensus on 
the necessity of follow-up [48,57-61]. 
In the 1970s, LFTs and chest radiographs were the modalities used for the follow-up of 
patients with primary uveal melanoma [39,62,63], and imaging of the liver—first with 
isotope scanning and later with US—became more common in the 1990s [18,40,64]. 
To date, each referral centre has its preferred imaging modality and frequency for early 
detection of metastases. The frequency of imaging varies depending on participation in 
ongoing trials and perceived risk of dissemination, informed by tumour histology and 
genetic profile, with high-risk patients often surveilled 4- to 6-monthly [11-15,18] based 
partly on the estimated tumour doubling times of metastases [16]. Clinical and histological 
features for high metastatic risk are as follows: large tumour size, involvement of the 
ciliary body, extraocular extension, high mitotic activity, and epithelioid cell type [65-
67]. Moreover, genetic prognosticators that favour metastatic spread are monosomy of 
chromosome 3, chromosome 8q gain, BAP1 loss, or class 2 gene expression profile [68,69].
In Europe, upper abdominal US is widely used for follow-up every 6–12 months for 10 to 
15 years, and CT and MRI are scheduled if a suspicious new lesion is detected [17-20,56], 
although some large centres also prefer MRI for early detection of metastases [11,21]. At 
tertiary-referral centres in the United States, the surveillance is often done using MRI, with 
a contrast agent for the liver and CT for the chest, abdomen, and pelvis, with the frequency 
based on perceived risk of metastases [22]. Hepatic US is used less frequently because of its 
relatively higher dependence on operator skill [70], its limitations in the obese [14], and a 
fear of malpractice claims in the absence of national practice guidelines [23]. LFTs are also 
often included in the review protocols [58]. 
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2.2.3 Imaging
The use of US as a surveillance tool is supported by its proven utility [14,18,71], even in 
the American population, although obesity makes it technically challenging and more 
time-consuming [14,70]. The tool is widely available and affordable, and it avoids the 
use of ionizing radiation [70]. A contrast agent can also be used for higher accuracy in 
characterising and detecting liver lesions [70]. There are only a few published studies on the 
role of US in the surveillance of hepatic metastases of uveal melanoma, and they report its 
sensitivity and specificity to be 96–100% and 14–88%, respectively (Table 1) [14,72]. The 
minimum diameter of detectable lesions in US has been suggested to be 5 mm [71]. Benign 
liver lesions, such as cysts or hemangiomas, were detected in 18% of surveilled patients with 
primary uveal melanoma [14]. Most centres with equivalent expertise in US and CT prefer 
US as a guide for percutaneous biopsy of suspicious liver lesions [70]. Furthermore, US can 
be used intraoperatively, and in a study that compared preoperative and intraoperative liver 
assessment with US, 30 metastases were detected by intraoperative US, compared to only 
11 by preoperative US [64]. 
A limitation of CT as a regular surveillance examination is the use of relatively large 
doses of ionizing radiation. A study using data from 1991 to 1996 suggested that 0.4% of 
all cancers in the United States can be traced back to radiation from CT scans and that 
radiation from such scans that are currently being performed may ultimately account for 
2% of all cancers in the future [73]. Nevertheless, CT is a useful staging method when 
examining pulmonary metastases, large hepatic metastases, and patients in whom MRI is 
contraindicated because of allergy to gadolinium or specified foreign bodies [9,50], and a 
CT scan takes less time than MRI [70]. If one metastatic hepatic lesion is detected on CT 
imaging, 90% of patients have multiple metastases in the liver [50]. In a single-centre study, 
CT was performed within one month of the diagnosis of primary uveal melanoma, and it 
detected benign hepatic lesions in 55% of patients [9].
MRI with a contrast agent is the most specific imaging modality, and it is at least as 
sensitive as CT, with sensitivity ranging from 67–100% and specificity from 80–99% (Table 
1) [13,17,74,75]. In a study of 100 patients with primary uveal melanoma who underwent 
a standard 1.5 Tesla MRI scan, the minimum diameter of the detectable hepatic lesions 
was as small as 1 mm [13]. Short T1 and long T2 patterns were reported in 27% of uveal 
melanoma patients, although short T1 and short T2 patterns were the most common 
[22,76]. However, MRI is more expensive and less accessible than CT and, especially, US. 
Although a global cost comparison is difficult because of differences in insurances and 
reimbursements, a rough estimation can be made from the Helsinki University Hospital 
price list for a self-paying patient: a hepatic US costs 93 €, while CT with contrast is 250 €, 
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and MRI with gadolinium and with a liver-specific contrast agent costs 350 € and 550 €, 
respectively. 
Metastases of uveal melanoma are 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-avid, similar to 
those of cutaneous melanoma. However, metastases of cutaneous melanoma most often 
home to the lymph nodes, whereas uveal melanoma typically disseminates to the liver, 
making the use of FDG-positron emission tomography (PET) less successful. Furthermore, 
normal mottled hepatic uptake of FDG obscures small FDG-avid lesions due to their poor 
target-to-background ratio [22], and consequently, MRI is more sensitive in detecting liver 
metastases than FDG-PET in uveal melanoma [17,75]. The sensitivity and specificity of 
PET are reported to be 45–100% and 67–100%, respectively (Table 1) [10,17,75,77-79]. A 
case series of 333 patients who underwent PET-CT for screening for metastases at the time 
of diagnosis of primary uveal melanoma found that PET-CT detected synchronous second 
primary cancers in 3% and benign hepatic lesions in 8% of the patients [10]. The use of 
PET-CT for regular follow-up is limited by the exposure to ionizing radiation [70].
Early metastases to the lung are infrequent when hepatic US already shows abnormalities 
[12,18,56]. The chest radiograph was abandoned from the surveillance protocol in the 
Helsinki University Hospital already in the 1990s. The reason was a study that concluded 
that only 2 of 46 patients diagnosed with metastatic uveal melanoma had pulmonary 
metastases that occurred together with hepatic metastases, and another 344 patients who 
did not develop metastases underwent up to 900 chest radiographs [18]. Many other centres 
have since followed this decision.
Table 1. Specificity and sensitivity of imaging modalities in detecting hepatic metastases of 










Hicks et al. 1998 
[72]
Baseline 100% 14% N/A 40




96% 88% N/A 263









Magnetic resonance imaging 





67% N/A 5 to >10 12




100% N/A 0.3–1.1 10
Piperno-




100% 80% 1–35 100
Francis et al. 2019 
[74]
Baseline 83% 99% N/A 145
Positron emission tomography
Kurli et al. 2005 
[77] 
Heterogeneousa 100% 100% N/A 20





100% 67% N/A 22





45% N/A 5 to >10 12
Klingenstein et al. 
2010 [79] 
Heterogeneousb 100% N/A 2.7–12 12c




100% N/A 0.3–1.1 10
Freton et al. 2012 
[10]
Baseline 100% N/A The smallest 
LDLM 9 mm
333
a Eighteen patients were imaged for staging and two before treatment of their primary uveal melanoma.
b Two patients were imaged for initial staging, one for a suspicious pulmonary finding, and nine for 
re-staging before or after local or systemic therapy for metastatic disease.
c Hepatic metastases were detected in 10 patients (83%), and two had bone or pulmonary metastases. 
LFTs, including alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (AP), and lactate dehydrogenase (LDH), are widely accepted in surveillance 
protocols, although the Collaborative Ocular Melanoma Study reported that LFTs, with a 
sensitivity of 14.7%, are poor surveillance tools [12,72]. These tests tend to become abnormal 
only when hepatic metastases reach an advanced stage, by which time any opportunities for 
prolonging life are usually lost [12,50]. However, LFTs have been reported to rise within the 
normal limits already during the half-year before metastases are detectable by imaging [80].
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If a metastasis is suspected, then a US- or CT-assisted fine-needle aspiration biopsy (FNAB) 
or, preferably, a core-needle biopsy (CNB) is recommended. Following the modified 
Callender system, metastases of uveal melanoma are of spindle cells, epithelioid cells, or 
a mixed cell type (consisting of spindle cells and epithelioid cells) [81]. The cut points are 
arbitrarily chosen, but in the tumour, node, metastasis (TNM) classification a spindle cell 
melanoma is determined to consist of ≥90% spindle cells, while an epithelioid cell melanoma 
consists of ≥90% epithelioid cells, and all other tumours are mixed cell melanomas. This 
cytological information was included in one [82] of the recent large tertiary-centre or 
nationwide studies on metastatic uveal melanoma [21,83-86]. The protocol of the College of 
American Pathologists recommends that pigmentation, the degree of necrosis, and mitoses/
mm2 should be included in the report [67,87,88]. The positive immunohistochemical stains 
include human melanoma black-45 (HMB-45) antigen, S-100 protein, MelanA, and less 
frequently, vimentin (though non-specific), tyrosinase, SRY-related HMG-BOX gene 10 
(SOX10), and microphthalmia transcription factor (MITF) [87,89-93]. Ki-67 is often used 
to estimate proliferation rate. 
The differential diagnosis is straightforward based on histomorphology if melanin is present; 
however, it can be challenging if the tumour is amelanotic because melanoma may mimic 
various histological patterns, making immunohistochemical stainings important [5]. A 
histopathologic review found that 7–10% of original cancer diagnoses in patients with uveal 
melanoma were incorrect if immunohistochemistry was not performed [5]. MelanA and 
HMB-45 positivity are rare, occurring in <1% and 0% of patients with non-small-cell lung 
cancer, respectively [94]. Cytokeratin-20 positivity is commonly used to confirm diagnosis 
of colon cancer, as it is expressed in 94% of colon cancer specimens. In uveal melanoma, 
cytokeratin markers are negative, although focal staining for simple epithelial cytokeratins 
may appear, and immunopositivity for cytokeratin-20 is distinctly unusual [92,95]. S-100 
protein is expressed in approximately 50%, MelanA in up to 20%, and HMB-45 in 2% of 
breast cancers [96-98]. It is advisable to use at least two immunohistochemical stainings for 
melanocytes such as HMB-45 and MelanA or S-100 protein in combination with epithelial 
markers, such as pan-cytokeratin, to exclude carcinoma if an amelanotic metastasis of uveal 
melanoma is suspected [87]. Finally, a mutation in GNAQ or GNA11 is found in more than 
90% of uveal melanomas [99,100]; however, BRAF mutation, which is present in 40–60% 
of patients with cutaneous melanoma, is almost entirely absent from uveal melanomas 
[34,35,101]. 
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2.3.1 Age and gender 
Age [7,37,40,85,102,103] and gender [7,21,37,40,85,104] have not been consistently 
associated with OS, although several investigators have associated older age [41,82,105,106] 
and male gender [41,105-107] with shorter OS (Tables 2 and 3). Especially the survival of the 
oldest age group is potentially confounded because of lead time bias and competing causes 
of death that are usually statistically unaccounted for [5]. In the tabulated publications, 
the median age at the time of diagnosis of metastatic uveal melanoma was 61–65 years 
[7,37,40,85,102,103,106], paralleling how the age categories were defined.
Table 2. Age at the time of diagnosis of metastases as a prognostic factor for OS in univariable 
analysis, tabulated alphabetically by author. Studies were included if hazard ratio (HR), or 
equivalent, and P-value were reported.a
Study No. patients 
in the study
Variable HR (95% CI) P-value
Eskelin et al. 2003 
[40]
91 Age, per 5-year increase 1.03 (0.93–1.14) 0.16





















Nicholas et al. 
2018 [85]
132 Age, per 1-year increase 1.01 (0.996–1.03) 0.14
Pons et al. 2011 
[103]
58 Age, per 1-year increase 0.99 (0.06–1.60) >0.05












Xu et al. 2018 [37] 73 Age, per 1-year increase 0.996 (0.990–1.002) 0.15
a Not included in the table: did not report HR and P-value [41], [105]; reported HR and P-value only for 
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Table 3. Gender as a prognostic factor for OS in univariable analysis, tabulated alphabetically by 
author. Studies were included if HR, or equivalent, and P-value were reported.a 
Study No. patients 
in the study
Variable HR (95% CI) P-value






































a Not included in the table: did not report HR and P-value [109], [105], [41].
b For consistency, the male gender was converted to reference.
c Risk rate.
The baseline characteristics of the primary uveal tumour are often left unreported in studies 
on metastases published in oncological journals [110], and they may not be associated 
with OS (Table 4) [21,40,102,111]. Orange pigment was associated with OS in univariable 
analysis (P = 0.005) in a single-centre study with 99 patients, but it was not predictive in the 
final multivariate-adjusted logistic regression model and not evaluated in any other study. 
Therefore, the association should be regarded with caution [82].
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Table 4. Characteristics of the primary tumour as a prognostic factor for OS in univariable 
analysis, tabulated according to different characteristics. Studies were included if HR, or 
equivalent, and P-value were reported.
Study No. patients 
in the study
Variable HR (95% CI) P-value
Eskelin et al. 2003 
[40]
91 Largest basal diameter, per 
1-mm increase
0.98 (0.97–1.04) 0.54














Valpione et al. 2015 
[111]
152 Larger basal diameter, per 
1-mm increase
0.92 (0.80–1.05) 0.40







Valpione et al. 2015 
[111]
152 Tumour thickness, per 1-mm 
increase
1.07 (0.91–1.27) 0.46
Lorenzo et al. 2018 
[82]
99 Orange pigment over tumour 4.20b (1.48–11.9) 0.005
Kodjikian et al. 
2005 [102]





Mariani et al. 2019 
[21]





Valpione et al. 2015 
[111]







































c The edition of a staging manual on which the TNM category is based, was not reported.
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2.3.3 
A longer distant metastasis-free interval (DMFI) might be a survival benefit (Table 5) 
[21,41,52,82,108,109,111,112]. However, lead time bias possibly influences the results [113].
Table 5. Distant metastasis-free interval as a prognostic factor for OS in univariable analysis, 
tabulated alphabetically by author. Studies were included if HR, or equivalent, and P-value were 
reported.a
Study No. patients 
in the study
Variable HR (95% CI) P-value


















Mariani et al. 2019 
[21]











Nicholas et al. 2018 
[85]
132 DMFI, per 1-month 
increase
0.998 (0.996–1.00) 0.015






Valpione et al. 2015 
[111]
152 DMFI, per 1-month 
increase
0.9 (NR) <0.001
Xu et al. 2018 [37] 73 DMFI, per 1-month 
increase
0.996 (0.990–1.002) 0.15
a Not included in the table: did not report HR and P-value [112], [109], [41]; reported HR and P-value for 




A better Eastern Cooperative Oncology Group (ECOG) performance status (Table 6), 
which is a measure of the general well-being and daily life activities of a patient with 
cancer, confers a survival advantage (Table 7) [21,40,82,85,86,103,106,108,111]. The 
European Organisation for Research and Treatment of Cancer (EORTC) multicentre phase 
II study with 24 patients reported no significance of performance status measured with 
the Karnofsky index (Table 6); however, this index was 100 for seven patients, 90 for 11 
patients, and 80 for six patients, and no patient had a Karnofsky index score less than 80 
[107]. 
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0 90–100 Fully active, able to carry on all pre-disease activities without 
restriction.
1 70–80 Restricted in physically strenuous activity but ambulatory and able to 
carry on light work.
2 50–60 Ambulatory and capable of all self-care but unable to carry out any 
work activities.
3 30–40 Capable of only limited self-care, confined to a bed or chair ≥50% of 
waking hours
4 10–20 Completely disabled. Cannot carry on self-care.
Table 7. Performance status (PS) as a prognostic factor for OS in univariable analysis, tabulated 
alphabetically by author. Studies were included if HR, or equivalent, and P-value were reported.a
Study No. patients 
in the study
Variable HR (95% CI) P-value












‘ECOG >1 seemed 











Kivelä et al. 2003 
[107]
24 Karnofsky index, per 
10-unit decrease in 
index
1.33 (0.78–2.27) 0.30
Lorenzo et al. 2018 
[82]
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Study No. patients 
in the study
Variable HR (95% CI) P-value










a Not included in the table: reported HR and P
adjusted by age and sex, not for the univariable analysis [108].
b Odds ratio.
c In multivariate analysis, P < 0.05.
d Only one P-value is given in the original publication.
2.3.5 Size of metastases
The largest diameter of the largest metastasis (LDLM) [40,82,85,106,107], larger percentage 
[111], larger area [21], and larger volume [40] of the metastases on baseline imaging are 
associated with a shorter OS (Table 8). 
Table 8. Size of metastases as prognostic factor for OS in univariable analysis, tabulated 
alphabetically by author. Studies were included if HR, or equivalent, and P-value were reported.
Study No. patients 
in the study
Variable HR (95% CI) P-value
Eskelin et al. 2003 
[40]
91 LDLM, per 1-cm increase 1.16 (1.10–1.24) <0.001
Eskelin et al. 2003 
[40]
91 Estimated total metastatic 
burden, per 1,000-cm3 
increase
1.51 (1.18–1.92) <0.001







Kivelä et al. 2003 
[107]
24 Median LDLM, per 10-mm 
increase 
1.13 (1.01–1.26) 0.032
Lorenzo et al. 2018 
[82]
99 Smaller largest diameter of 
the largest liver metastasis




Mariani et al. 2019 
[21]












Nicholas et al. 2018 
[85]
132 Largest liver metastasis size, 
per 1-mm increase
1.07 (1.03–1.12) 0.0010
Valpione et al. 2015 
[111]
152 Liver substitution, per <20%, 
20≤50%, 50%≤ increaseb
1.6 <0.001
a Odds ratio; for consistency, the larger largest diameter of the largest liver metastasis was tabulated as a 
reference.
b Equivocal what was used as a reference, but the authors state that increasing liver substitution was 
associated with a worse OS.
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2.3.6 Sites of metastases
The presence of liver metastases has been reported to be associated with shorter survival 
(Table 9) [41,85,86,105]. Moreover, concomitant extrahepatic and hepatic metastases have 
been associated with worse survival [21,37]. Bone metastases were an adverse prognostic 
factor only in multivariable analysis, unlike in cutaneous melanoma; however, the number 
of patients who had bone metastases was small, and it was not studied by other researchers 
[85]. In addition, a higher number of liver metastases [102,103] were associated with a 
shorter OS. 
Table 9. Sites of metastases as a prognostic factor for OS in univariable analysis. Studies were 
included if HR, or equivalent, and P-value were reported.a
Study No. patients 
in the study
Variable HR (95% CI) P-value














Kodjikian et al. 2005 
[102]







Pons et al. 2011 
[103]





Mariani et al. 2019 
[21]

































Nicholas et al. 2018 
[85]





a Not included in the table: did not report HR and P-value [105], [41].
b Risk rate.
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Elevated AP [40,85,106,112] and LDH [21,40,82,85,86,106,108,111] are mostly strongly 
associated with a shorter OS, but associations with elevated AST [40,82], ALT [40,82], 
gamma-glutamyl transferase (GT) [108], and neutrophil lymphocyte ratio [85] have also 
been reported (Tables 10–13). The EORTC multicentre phase II study, which reported no 
association with AP level, included only one patient whose AP level was >2.5 x the upper 
normal limit (UNL) [107]. For comparability, the level of liver enzymes in serum or plasma 
was best expressed as a fraction of the upper normal limit for the specific enzymes in the 
laboratory where testing was performed [110]. 
Table 10. AP as a prognostic factor for OS in univariable analysis, tabulated alphabetically by 
author. Studies were included if HR, or equivalent, and P-value were reported.a





Eskelin et al. 2003 
[40]
91 AP, per 100-IU/L increase 1.49 (1.30–1.71) <0.001














Kivelä et al. 2003 
[107]
24 AP, relative to the UNL 
(per 1X increase)
1.75 (0.97–3.15) 0.061
Lorenzo et al. 2018 
[82]
99 AP
≤1.0 x the UNL




Nicholas et al. 2018 
[85]
132 AP, per 1-unitc increase 1.003 (1.002–1.004) <0.0001
a Not included in the table: did not report HR and P-value [112].
b Odds ratio.
c Scale not mentioned.
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Table 11. LDH as a prognostic factor for OS in univariable analysis, tabulated alphabetically by 
author. Studies were included if HR, or equivalent, and P-value were reported.a





Eskelin et al. 2003 
[40]
91 LDH, per 100-IU/L 
increase
1.06 (1.03–1.08) <0.001









































Nicholas et al. 2018 
[85]
132 LDH, per 1-unitc 
increase 
1.00 (1.00–1.00) <0.0001d
Valpione et al. 2015 
[111]
152 LDH, x UNL, per 1-unit 
increase
1.6 0.014
a Not included in the table: reported HR and P
adjusted by age and sex [108].
b Odds ratio.
c Scale not mentioned.
d Seems statistically implausible.
Table 12. AST as a prognostic factor for OS in univariable analysis, tabulated alphabetically by 
author. Studies were included if HR, or equivalent, and P-value were reported. 





Eskelin et al. 2003 
[40]
91 AST, per 10-IU/L increase 1.25 (1.14–1.36) <0.001
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Table 13. ALT as a prognostic factor for OS in univariable analysis, tabulated alphabetically by 
author. Studies were included if HR, or equivalent, and P-value were reported. 





Eskelin et al. 2003 
[40]
91 ALT, per 10-IU/L increase 1.23 (1.13–1.33) <0.001















2.3.8 Presence of symptoms
Symptoms attributable to metastases are associated with a shorter OS (Table 14) [37,40,82], 
but lead time bias and small numbers of patients with symptoms (10–41 patients per study) 
might affect the results.
Table 14. Symptoms as a prognostic factor for OS in univariable analysis, tabulated 
alphabetically by author. Studies were included if HR, or equivalent, and P-value were reported.






















Attendance to regular review for metastases may be statistically associated with survival 
(Table 15) [40,41,82], but the effect of lead time bias is likely significant, albeit difficult to 
analyse because of inconsistent surveillance protocols.
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Table 15. Attendance to follow-up as a prognostic factor for OS in univariable analysis. Studies 
were included if HR, or equivalent, and P-value were reported.a





Eskelin et al. 2003 
[40]






Lorenzo et al. 
2018 [82]






a Not included in the table: did not report HR and P-value [41].
b The frequency of follow-up was not reported.
c Odds ratio.
2.4 STAGING SYSTEMS
Staging is universally recommended for prognostication, for research purposes, and 
to identify patients who may benefit from therapies [58]. The most common cancer 
classification system was developed by the International Union Against Cancer, the 
American Joint Committee on Cancer (AJCC), and the American College of Surgeons 
[117]. It is known as TNM classification, and it has been published since 1977, and for 
uveal melanoma since 1983 [118]. TNM staging is currently performed according to its 8th 
edition, published in Chicago, USA, and effective as of 2017. 
Additionally, three dedicated staging systems have been developed to refine the 
prognostication of metastatic disease: 1) the Helsinki University Hospital Working 
Formulation (WF) in 2003, 2) the prognostic nomogram for metastatic uveal melanoma 
from the Veneto Oncology Institute and the Mayo Clinic in 2015, and 3) the recent 
prognostic nomogram for hepatic metastases of uveal melanoma from the Institut Curie in 
2019 [21,40,111,119].
2.4.1 Tumor, Node, Metastasis staging
The current TNM classification for ciliary body and choroidal melanomas, the AJCC Staging 
Manual, 8th edition [67], is essentially identical to the 7th edition but is only validated as 
regards the primary tumour. The classification for the 7th edition was empirically derived 
from a collaborative database of 7,359 patients [120]. Furthermore, regarding the primary 
tumour, it was independently validated by a study of 3,217 patients [118] and is supported 
by several large single-centre studies [121,122]. 
The classification is based on the anatomical extent of the primary tumour (T), including 
the presence of regional lymph node metastases (N) and the presence of systemic metastases 
(M). 
Review of the literature
35
Primary ciliary body and choroidal melanomas are classified in categories T1a–T4d 
according to tumour size and involvement of the ciliary body and extrascleral tissues 
up to 5 mm in diameter [67,120]. In addition, T4 includes a subcategory for extrascleral 
extensions >5 mm in diameter (T4e). 
These T-categories are combined to form stages—I, IIA–B, IIIA–C, and IV—that differ 
from one another in terms of survival [67]. Of ciliary body and choroidal melanomas, 
21–32% are classified as stage I, 32–34% as stage IIA, 22–23% as stage IIB, 9–17% as stage 
IIIA, 3–7% as stage IIIB, 1% as stage IIIC, and 2% as stage IV [118,120]. Stage IV includes 
patients who either have invasion of regional lymph nodes or discrete tumour deposits in 
the orbit that are not contiguous to the eye or have distant metastases. 
The invasion of regional lymph nodes—preauricular, submandibular, or cervical—and 
discrete tumour deposits in the orbit are denoted as N1-category and are rare [67]. 
Patients with metastases (M1) are categorised into subcategories M1a–M1c by the LDLM, 
where M1a denotes an LDLM ≤3 cm, M1b indicates an LDLM of 3.1–8.0 cm, and M1c 
classifies an LDLM ≥8 cm. The subcategories M1a–M1c correlate strongly with OS [67]. 
These subcategories are not used to create substages to stage IV. 
Information on cytogenetic prognosticators, gene expression profiling, and molecular 
genetic prognosticators are not yet included in the AJCC staging system because they 
have only recently emerged, and the follow-up of patients with genetic data is short. A few 
studies have recently reported that AJCC staging can be supplemented with chromosome 
status [123,124] or gene expression profile status [125].
The WF was the first substaging system to predict survival after metastatic uveal 
melanoma to improve the design, analysis, and reporting of trials [40,119]. The WF is 
based on a multivariable model—built with 91 patients by using Cox proportional hazards 
regression—that identified the Karnofsky index/ECOG performance status, LDLM, 
and serum or plasma AP level as independent predictors for survival [40]. The strongest 
prognostic factor in the WF was the LDLM, which was later incorporated into the 7th 
edition of the AJCC as the M1a–M1c subcategories [40,67]. Additionally, it was adjusted 
for time on chemotherapy.
The multivariable model is used to calculate individual predicted survival for newly 
diagnosed patients with metastatic uveal melanoma and to assign them to stages IVa, IVb, 
and IVc. These stages correspond to a predicted survival ≥12 months, <12 to 6 months, and 
<6 months after diagnosis of metastases, respectively. 
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The WF was validated by the European Ophthalmic Oncology Group (OOG) [119]. 
Members of the OOG from seven medical and ocular oncology services provided data of 249 
consecutive patients who died of metastatic uveal melanoma. The diagnosis of metastases 
was based on autopsy, biopsy, or typical clinical course (progressive hepatic metastases in 
the absence of second cancer). One hundred and sixty-eight patients had received single-
agent or combination chemotherapy; four patients had undergone chemoembolisation; six 
patients had received interferon (IFN) usually with tamoxifen; 11 patients had received 
BSC; 47 patients had undergone surgical resection with or without systemic therapy; nine 
patients had been immunised with tumour vaccine; and four patients had received various 
other treatments. Of the patients, 44%, 44%, and 12% were staged to IVa, IVb, and IVc, 
respectively. The corresponding median OS was 19, 11, and 4.6 months, respectively, and 
it shortened with an increasing stage (P < 0.001). The 12- and 24-month survival rates 
were 53% and 22%, respectively. The median OS of 47 patients with surgical resection was 
28 months for stage IVa and 26 months for stage IVb, and only one patient in stage IVc 
survived 17 months (P = 0.69). The median OS of 201 patients without surgical resection 
was 17, 10, and 4.6 months (P < 0.001) for stage IVa, IVb, and IVc, respectively. 
2.4.3 Staging nomograms
The first prognostic nomogram for disseminated uveal melanoma was built with the data of 
152 patients from the prospective melanoma database at the Melanoma Oncology Unit of 
the Veneto Oncology Institute, Padova, Italy, and it was validated by a dataset from Mayo 
Clinic, Rochester, Minnesota, comprising 102 patients [111]. This nomogram includes LDH, 
DMFI, percentage of liver involvement, and ECOG performance status, and it predicts 6-, 
12-, and 24-month survival. The 12- and 24-month survival rates for the building dataset 
were 63% and 35% and for the validation dataset 62% and 36%, respectively.
The second prognostic nomogram was modelled with the data of 224 patients from 
the Institut Curie, Paris, France [21]. The following four factors were selected for the 
nomogram: DMFI, the number of liver metastases, the area of the largest metastasis, and 
LDH. The nomogram predicts 6-, 12-, and 24-month survival, and the survival rates were 
88%, 68%, and 26%, respectively.
The WF [40,119], Veneto-Mayo [111], and Curie [21] nomograms share components—the 
size of metastases [21,111,119], LFT [21,111,119], and performance status [111,119]—but 
these components are assessed differently. 
The WF and the Veneto-Mayo nomogram are modelled regardless of metastatic site, 
whereas the Curie nomogram includes only patients with liver metastases, although 
concomitant extrahepatic disease is also allowed, and it requires that a liver MRI at the time 
of diagnosis of metastases is available.
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The WF includes AP level because it displayed a stronger association with survival than 
LDH; however, the LDH level was known for <50% of patients, which possibly influenced 
the statistics. In the Veneto-Mayo nomogram, LDH was chosen over AP for the final 
model, although AP was also tested but omitted from the results. In the Curie nomogram, 
LDH was included, and AP was not analysed. LDH is also included in the TNM staging of 
cutaneous melanoma.
The liver involvement was measured as percentage of liver in the Veneto-Mayo nomogram, 
based on their hypothesis that it is the best indicator of the effective volume of hepatic 
disease. LDLM was analysed but left unreported. In the WF, the percentage of liver 
involvement was not reported, but LDLM was analysed and found to be at least as good 
as metastatic burden. The Curie nomogram analysed only the surface area of the largest 
metastasis, assuming that the total number of hepatic metastases is associated with the 
surface of the largest metastasis, leaving LDLM and the percentage of hepatic invasion 
unreported because the latter would ‘be a time-consuming task’. 
DMFI was analysed in the building dataset of the WF, but proved not to be an independent 
prognostic factor, whereas it was included in the other two systems. 
According to my Scopus citation search on May 04, 2020, the Veneto-Mayo and Curie 
nomograms have not been applied to stage patients in any published article, and the WF 
has been used in three publications [107,126,127].
There is no consensus on the treatment of metastatic uveal melanoma. Few national 
guidelines exist: those in Canada [57], France [59], the United Kingdom [58], Scotland [61], 
and the United States [60]. All of them are evidence-based, and none was developed based 
on an expert consensus only; however, in a recent systematic analysis of the guidelines 
[57,58,60] consistently poor values were achieved for the usability of the recommendations 
for clinical practice [128]. There is also no shared opinion on the best first-line treatment 
modality in the present guidelines.
Several endpoints have been used in oncological clinical trials: OS, progression-free 
survival (PFS), and time to progression (TTP). OS is defined as the time from enrolment 
or treatment initiation to death from any cause, and it is generally easily and precisely 
measured. However, it requires longer follow-up than PFS and TTP, and it might be affected 
by subsequent therapies if such a treatment that affects the prognosis exists [129,130]. 
Importantly, OS possibly includes deaths due to other reasons, such as second synchronous 
cancer or other unrelated medical conditions [5]. 
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PFS is defined as the time from randomisation until objective tumour progression or 
death from any cause, whichever occurs first [130]. PFS can be assessed earlier and with a 
smaller sample size than OS, and it is generally based on defined assessment criteria [131]. 
However, especially if not masked, it is potentially subject to assessment bias. The definition 
of PFS can also vary among studies, and frequent radiological or laboratory examinations 
are needed. 
TTP is defined as the time from randomisation until objective tumour progression. It does 
not include deaths that are censored [130]. 
Both the United States’ Food and Drug Administration (FDA) and the European Medicines 
Agency (EMEA) require that the investigational product provides clinical benefit [130,132]. 
The FDA considers OS as the most reliable endpoint in cancer research, and PFS and TTP 
may support either regular or accelerated approval [129,130]. For the EMEA, acceptable 
primary endpoints include OS and PFS. If PFS is the selected primary endpoint, then OS 
should be reported as a secondary one [132]. From the patient’s point of view, OS may be a 
more meaningful outcome than PFS or TTP [113]. 
The chemotherapy regimens used for metastatic uveal melanoma are often adopted from 
protocols for cutaneous melanoma. Fifteen studies reported individual-level data on 
conventional chemotherapy (CHT) to treat metastatic uveal melanoma, including 411 
patients, with five to 85 patients per study (Table 16). CHT was used as the control for 
another regimen in 33% of the studies [24,25,133-135].
Chemotherapy agents included dacarbazine, temozolomide, fotemustine, and 
docosahexaenoic acid–paclitaxel, as well as combinations of gemcitabine and treosulfan; 
temozolomide and bevacizumab (anti-vascular endothelial growth factor); cisplatin, 
dacarbazine, and vinblastine; and gemcitabine, treosulfan, and cisplatin. No less than 10 
studies were prospective—two of them randomised ones, and one being a large multicentre 
randomised trial of the EORTC that used fotemustine intravenously in one arm [24]. 
Fostemustine is selectively absorbed by the liver and not registered in Finland where a 
combination of temozolomide, lomustine, and vincristine was typically chosen in the 2010s 
[136,137]. 
The reported median OS ranged from 4.6 to 17.0 months, and none of the studies applied 
staging, although a prospective study tabulated the parameters needed for staging by the 
WF [138].
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Six studies reported individual-level data on chemoimmunotherapy with IFN or IL (CIT), 
including 107 patients, with three to 48 patients per study (Table 17). The median OS 
ranged from 3.7 to 41 months. Three of the studies were conducted in Finland and were 
the only ones that applied staging of metastases [107,126,127]. The EORTC phase II study 
with bleomycin, vincristine, lomustine, and dacarbazine (BOLD) with IFN was conducted 
to confirm the reported response rate of 15–20% [126,147]; however, it suggested no major 
benefit in OS [107]. 
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2.5.3.3 
Immunotherapy boosts the immune system with the aim of destroying the cancer cells. 
Twenty-one publications incorporating 704 patients, with five to 83 patients per study, 
evaluated anti-cytotoxic T-lymphocyte associated protein (CTLA)-4, anti-programmed 
cell death (PD)-1, anti-programmed cell death ligand-1 (PD-L1), immune-mobilising 
monoclonal T-cell receptor against cancer (ImmTAC) platform, or dendritic cell vaccine 
(Table 18). Anti-CTLA-4 antibodies included ipilimumab with 275 patients, the largest 
number of patients, and tremelimumab. Anti-PD-1 antibodies included nivolumab 
and pembrolizumab, while the anti-PD-L1 antibodies tested were atezolizumab 
and avelumab. The combination of ipilimumab and nivolumab was administered to 
27 patients, ipilimumab and pembrolizumab to nine patients, and ipilimumab and 
nivolumab or pembrolizumab to 79 patients. Tefentafusp and vaccine were tested in 14 
patients each. Ten studies were prospective, and none were randomised; 42% were first-
line treatments; none were staged; and the median OS ranged from 4.6 to 20 months for 
all studies. For combined ipilimumab + anti-PD-1 or PD-L1 treatments, the median OS 
ranged from 14 to 19 months [151-155], and only one of these studies concerned a first-
line treatment [151]. While most patients do not seem to benefit from immunotherapies, 
evidence has recently emerged that molecular targeted immunotherapy might benefit a 
small subset of patients who carry an MBD4 mutation [33,156].
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In 11 studies, 294 patients (eight to 97 patients per study) received targeted therapy (Table 
19). The drugs included imatinib, sorafenib, sunitinib, cabozantinib, selumetinib, and 
ganetespib, and in three studies, they were combined with a conventional chemotherapeutic 
agent. Nine studies were prospective, and three of them were randomised. Targeted 
therapy was applied as the first-line treatment in 28% of the patients, and the median OS 
ranged from 6.3 to 16 months. Furthermore, the SUMIT trial—the first-ever clinical trial 
in metastatic uveal melanoma designed to register a drug with a regulatory body—tested 
selumetinib in combination with dacarbazine; however, it failed to document improved 
outcomes [25,171]. Immunotherapy and targeted therapy have revolutionised the treatment 
of metastatic cutaneous melanoma, but in metastatic uveal melanoma, their effect is limited, 
probably due to the lower mutational load and different driver mutations [101,172,173], 
and although c-KIT is often expressed in uveal melanoma, it does not translate into clinical 
efficacy of imatinib [174].
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A total of 14 patients were analysed in a prospective non-randomised phase II trial with 
a median OS of 11 months (Table 20). The used immunosuppressant was everolimus 
combined with pasireotide. 

























































































































































14 0 (0%) NR NR Treatment 11 USA
Local therapies, especially radical surgical resection (R0) is considered the best treatment 
whenever possible, while chemotherapy is recommended if a patient is not eligible for 
local therapies [107]. Regrettably, the number of patients eligible for local therapies is 
limited because of diffuse disease burden or poor overall performance status [11,182]. 
Eleven studies reported the results of surgical resection incorporating 528 patients, with 
five to 157 per study (Table 21). The median OS ranged from 11 to 90 months and was 
prolonged if the resection was more complete. Although a complete resection is preferred, 
only 25–50% of the patients underwent a radical resection [19,52,104,183,184]. Surgical 
resection was applied to metastases located in the liver, lung, stomach, bone, adrenals, and 
lymph nodes. Of the patients with liver metastases, 6–44% underwent metastatic debulking 
[11,52,104,184,185]. In a Dutch nationwide study, 22% of the patients with metastatic uveal 
melanoma received local treatment regimens [86].
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Liver metastases obtain their blood supply primarily via the hepatic artery, and the normal 
liver tissue obtains its supply via the portal vein, allowing the chemotherapeutic agent to 
be delivered selectively to the cancer cells via the hepatic artery. Eleven studies evaluated 
hepatic intra-arterial chemotherapy (HIA) in 370 patients, with seven to 101 patients per 
study (Table 22). Five studies were prospective, with one randomised controlled trial. 
The chemotherapeutic agents included predominantly fotemustine and melphalan, but 
carboplatin; and combinations of cisplatin, vinblastine, and dacarbazine were also applied. 
The EORTC multicentre randomised controlled trial with 86 patients in the HIA arm found 
no difference in OS between intravenous and intra-arterial fotemustine [24]. The median 
OS ranged from 2.9 to 22 months. 
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In transarterial chemoembolisation (TACE), the blood supply of the tumour from the 
hepatic artery is cut off, and a chemotherapeutic agent is then trapped within the tumour. 
While a gelatin sponge was the most common material used to cut off the blood supply, 
polyvinyl alcohol particles, starch microspheres, and drug-eluting beads were also used. 
Sixteen studies reported on 522 patients (10 to 125 per study), and none were staged (Table 
23). Six studies were prospective, with a maximum of 30 patients, and two of them were 
randomised. The most commonly used chemotherapeutic agents included cisplatin and 
fotemustine. The oldest study that the whole search strategy caught involved TACE [196]. 
The median OS ranged from 5.1 to 28.8 months. 
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The two studies that included patient-level survival data on immunoembolisation (IE) 
incorporated embolisation of the hepatic artery with granulocyte-macrophage colony 
stimulating factor (GM-CSF) instead of a cytotoxic agent. Both were of a prospective 
nature—a phase I and a phase II study—including 59 patients with a median OS of 14 and 
22 months (Table 24).
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a The median OS is reported for 34 patients in intent-to-treat analysis, whereas the Kaplan-Meier plot 
includes 31 radiographically assessable patients.
In isolated hepatic perfusion (IHP), the liver is temporarily isolated from the blood 
circulation and perfused with high doses of a chemotherapeutic agent. The by-passing of 
the liver is achieved by placing a catheter into the hepatic artery and another catheter into 
the vein that drains blood from the liver. IHP, whether open or percutaneous, is a complex 
procedure, and although it has been under clinical investigation for six decades, its 
application has been limited because of high morbidity and mortality [209,210]. A Swedish 
study reported a 1-month mortality of 7%, but recently, with refinement of the technique 
and patient selection, the rate decreased to 2% [211,212]. Nine studies from seven research 
groups included a total of 266 patients, with three to 61 patients per study (Table 25). Two of 
the studies were prospective, and none were randomised. The chemotherapeutic agent that 
was utilised was melphalan with or without tumour necrosis factor (TNF)-α or oxaliplatin. 
The median OS ranged from 9.6 to 27 months. 
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51 NR 9 
(18%)
NR Treatment 15.3 UK, 
USA
Melphalan Vogl [219] 2017 Retrospec-
tive case 
series
18 7 (39) 5 (28) NR Treatment 9.6 DE
a No OS reported; digitised Kaplan-Meier estimate.
In selective internal radiation therapy (SIRT), microspheres composed of resin or glass 
particles bound to yttrium-90, which is a high-energy beta-emitting isotope, are implanted 
into the hepatic arterial circulation. The resin bead microspheres are small enough to enter 
the tumour circulation and emit radiation that destroys cancer cells but too large to enter 
capillaries and spread to the lungs, which must be tested before treatment on a patient 
level. Six studies evaluated SIRT incorporating 124 patients, with eight to 50 patients 
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per study (Table 26). No prospective studies have been published on SIRT. The median 
OS ranged from 2.8 to 19 months. In a nationwide Finnish study, 18 patients without 
extrahepatic metastases and ineligible for surgical resection received SIRT as a first-line or 
salvage therapy, and the median OS after SIRT was 2 months longer than for the historical 
chemotherapy group (P = 0.047); moreover, the procedure was well tolerated. In recent 
years, SIRT has become the primary local treatment modality of liver metastases not 
eligible for surgical resection in Finland [51,136]. 
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a Prior treatment reported for all 58 patients, and not specifically for the 50 patients who had a pre-
treatment PET-CT and were included in the Kaplan-Meier plot.
b No OS reported; digitised Kaplan-Meier estimate.
c TARE, Transarterial radioembolisation.
Thermal destruction of liver metastasis is induced by stereotactic radiofrequency ablation 
(RFA) and laser-induced thermotherapy. Two studies evaluated the use of liver-directed 
thermotherapy in uveal melanoma hepatic metastases incorporating 25 patients (Table 27). 
The reported OS ranged from 29 to 38 months, and both studies were retrospective. 
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a In the original publication, the median survival was reported as 38 months; according to personal 
communication, this was calculated by the actuarial method and is 36.3 months by the Kaplan-Meier 
method.
b The authors state, ‘Limitations of our study are the small number of patients and the inhomogenous 
population concerning various treatments prior to the laser-induced thermotherapy like 
immunochemotherapy and TACE’.  
c Digitised Kaplan-Meier estimate approved by personal communication.
Seven studies reported individual-level survival data on patients with metastatic uveal 
melanoma who received BSC (Table 28). Altogether, they comprised 518 patients (11–
191 patients per study), and four studies omitted prognostic factors on a patient level 
[7,11,37,83,85,86,103]. Of all patients included in these studies, 15–88% received BSC. 
Patients were often older and had more advanced disease, making comparison without 
staging, which was not included in any of the studies, unfeasible. The publications lacked 
a detailed description of BSC / palliative treatment / no treatment—a common issue in 
medical literature [227]. 
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Table 28. Studies reporting individual-level survival data on BSC. 




Median OS (months) 
Gragoudas et al. 1991 [7] 44/145 (30) No 2.0
Pons et al. 2011 [103] 23/58 (40) Yes 8.03 (95% CI, 5.35–16.30)
Gomez et al. 2014 [11] 137/155 (88) No 8 (range, 1–30)
Lane et al. 2018 [83] 191/620 (31) No 1.7 (IQR, 0.66–3.5) 
Xu et al. 2019 [37] 11/73 (15) Yes 4.9
Nicholas et al. 2018 [85] 43/132 (33) No 3.8 (95% CI, 1.9–5.9)
Jochems et al. 2019 [86] 69/175 (39) Yes 6a
a No OS mentioned; approximated from Kaplan-Meier graph.
Given the assumption that dormant micrometastases harbour in the liver or in bone 
marrow, as recently postulated, years before the clinical diagnosis can be made, adjuvant 
therapy would be a logical strategy in uveal melanoma [228,229]. Attempts have been 
made with dacarbazine, IFN [230], combined dacarbazine and IFN [231], intra-arterial 
fotemustine [232], sunitinib [233], ipilimumab [234], and dendritic cell vaccine [235]. 
However, the studies either failed to demonstrate a longer OS [230-232], were very small 
(≤20 patients) [234,235], or did not include a proper control group [233].
2.5.7 Time trends of overall survival
Survival rates in different time periods were compared in three retrospective single-centre 
studies. A large study, which included 661 consecutive patients with metastatic uveal 
melanoma, reported no improvement in survival rate between the periods 1982–1991, 
1992–2001, and 2002–2009 [83], nor did a study of 73 patients with uveal melanoma 
metastatic to the liver between 2004–2011 and 2012–2016 [37]. However, an assessment 
of the experience of a single institution with uveal melanoma metastatic to the liver 
suggested that a shift from CHT to liver-directed treatment improved survival. It included 
730 consecutive patients from the time periods 1971–1993, 1998–2007, and 2008–2017; 
between the first versus second and the first versus third time periods, OS improvement 
was observed (P < 0.001) [84]. However, this analysis might be subject to both lead time 
bias, from changes in surveillance methods, and selection bias.
Given the small number of patients resulting from the rarity of uveal melanoma, few 
randomised trials have been conducted: hepatic IA versus IV fotemustine [24], selumetinib 
plus dacarbazine versus placebo plus dacarbazine [25], immunoembolisation versus bland 
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embolisation [26], intrahepatic cisplatin with versus without polyvinyl sponge [27], and 
cabozantinib [28,135]. The largest trial included 171 patients [24]. 
Furthermore, a few studies on the real-life outcomes of metastatic uveal melanoma in 
tertiary care centres have been published with 89–730 actively treated patients per study 
[10-12,15], including only one nationwide study with 175 patients [86]. However, they 
often have considerable gaps in reporting patient-level prognostic factors and treatments 
administered, or they lack proper control groups [110,236,237]. Additionally, lead time 
bias poses a problem in interpreting results [48,84]. Unless the review for metastases is 
similar in the centres, comparing the results of treatment modalities is impossible, even in 
otherwise controlled trials.
Researchers often fit multivariate models ad hoc for metastatic uveal melanoma, typically 
by a data-driven, forward or backward stepwise approach, ignoring prior knowledge [21,
37,40,82,85,103,104,108,111]. Such models typically fit a small sample but are unlikely to 
be repeatable. Alternatively, researchers plot survival according to single predictors. Bias 
from other factors makes comparisons between studies difficult, if not impossible [110]. 
For all considerations above, the staging of patients is essential. Nevertheless, only three 
studies reported any staging [107,126,127], and an additional one provided the information 
to calculate it [138]. 
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The goal of this thesis is to advance the analysis and interpretation of OS in metastatic uveal 
melanoma. 
The specific aims of this study are as follows:
I To provide a meta-analysis of OS in published, peer-reviewed studies on metastatic 
uveal melanoma containing patient-level data (Study I). 
II To describe a nationwide cohort whose metastatic disease was diagnosed between 
1999 and 2016 (Studies II, III, and IV). 
III To evaluate the agreement of radiological screening modalities at the time of diagnosis 
of metastatic uveal melanoma in the nationwide cohort to ultimately advance the 
formulation of a nationally and potentially universally acceptable screening strategy 
for metastases, consequently enhancing comparability in treatment trials in the future 
(Study II).
IV To evaluate the OS, stratified by validated prognostic stages, of patients who only 
received BSC in the nationwide cohort in order to publish a historical benchmark to 
facilitate correct interpretation of OS outcomes in trials (Study III). 
V To report the stage-stratified OS and treatment modalities of actively treated patients 
in the nationwide cohort so as to identify any treatment modalities that might be 
associated with a shorter- or longer-than-average survival (Study IV).
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4.1.1 Study I
I planned the meta-analysis according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) 2009 guidelines [238]. I searched PubMed for 
literature published between January 1, 1980 and March 29, 2017 for the terms uveal 
melanoma, choroidal melanoma, ciliary body melanoma, ciliochoroidal melanoma, 
iridociliary melanoma, iris melanoma, intraocular melanoma, and ocular melanoma, and 
for the additional terms metast* or stage IV, and treatment. Patient-level data were required 
in either Kaplan-Meier plot or numerical form. Kaplan-Meier plots were digitised; then, the 
patient-level survival times of each treatment modality were constructed and pooled, and 
the median OS times were reported and analysed. The analysis included 78 peer-reviewed 
studies, with 2,494 patients treated for metastatic uveal melanoma. 
4.1.2 Studies II–IV
Studies II–IV enrolled consecutive patients with primary uveal melanoma, managed 
in the Ocular Oncology Service, Department of Ophthalmology, Helsinki University 
Hospital, Finland, who developed metastases between January 1999 and December 2016. 
Common exclusion criteria for Studies II–IV were no diagnosis until autopsy, metastases 
not consistent with uveal melanoma, and concurrent active second cancer. For a detailed 
description of the exclusions, see Figure 1. 
Patients who underwent CT, MRI, or both within 60 days of upper abdominal US were 
eligible for Study II. 
Patients eligible for Study III were those who received only BSC, including palliative 
radiotherapy to control pain in five patients. 
Patients who received active treatment were eligible for Study IV. 
I obtained charts from all hospitals that participated in the management of metastatic uveal 
melanoma, and I recorded the following: gender, age, date of diagnosis of the primary 
tumour and metastases, TNM stage [67,118,120], participation in regular follow-up to 
detect metastases early [18], symptoms of metastases, LFTs, LDLM, sites of metastases, 
ECOG performance status [114], date of treatment decision (including decision on BSC), 
WF [40,119], modality of treatment, and date of death and registered COD. Surveillance 
included annual LFTs and US, followed by MRI or CT when metastases were suspected. 
Since 2014, surveillance has been semi-annual for patients representing TNM stage III. 
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For Study II, I recorded whether the original US and CT/MRI imaging reports described 
the presence and number of metastases consistently. If US or CT/MRI examination was 
interpreted as metastatic whereas the other one was not, then an experienced radiologist 
reviewed the CT/MRI images. 
For Study IV, patients were divided by first-line treatment strategy (systemic versus local). 
Based on my previous meta-analysis (Study I), I prospectively identified the following 
systemic modalities: CHT, CIT, checkpoint inhibitors (CPI), protein kinase inhibitors (PKI), 
and vaccine therapies. Additionally, data on patients treated with IFN/IL monotherapy 
were available. Prospectively identified local treatments were surgery, SIRT, TACE, and 
other liver-directed therapies (stereotactic RFA, brachytherapy). 
Follow-up ended on December 31, 2018. 
I aimed to include as many patients with histologically confirmed metastasis as possible and 
adapted the definitions of the Collaborative Ocular Melanoma Study to ascertain whether 
metastatic uveal melanoma was present [5,239]. Samples of metastases were obtained from 
biobanks and institutes of pathology. 
The code ‘dead with melanoma metastases, confirmed metastases’ was used if the original 
pathology report mentioned moderate to heavy melanin or either HMB-45 or MelanA/
MART-1 immunopositivity. If the original pathology report mentioned none of these 
characteristics and was not an FNAB, then I obtained the original specimen for review. 
Moreover, if melanin was equivocal, then I ordered HMB-45, MelanA/MART-1, and pan-
cytokeratin immunostainings [5]. The code ‘suspected metastases’ was used if only an FNAB 
was available or no histopathologic confirmation had been sought but clinical findings 
(hepatomegaly, elevated LFT, liver imaging) were consistent with progressive metastases. 
The code ‘possible metastases’ was used if the death certificate specified metastatic 
melanoma as the COD but clinical data were inconclusive, or if the specified COD was 
other than metastases but clinical findings were consistent with metastases. Finally, the 
code ‘dead, not consistent with melanoma metastases’ was used if the histopathology was 
not diagnostic of metastatic melanoma, clinical data were inconclusive, and the patient was 
excluded—this applied to one patient in the cohort (Figure 1). 
In Study II, metastases were biopsy-confirmed in 67% of patients, whereas a biopsy was 
not performed on 33% of patients (largely those who were offered BSC because of their 
advanced age or poor general health). The COD was relevant for Studies III and IV, 
whereas for Study II, which concentrated on diagnostics, it was irrelevant. After central 
review with an experienced ophthalmic pathologist, 47% had confirmed metastasis, 46% 
suspected metastasis, and 7% possible metastasis in Study III, compared to 71%, 27%, and 
2%, respectively, in Study IV. 
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Figure 1. Study flow chart.
I used the WF validated by the OOG for the calculation of the individually predicted 
median OSs to stage the patients at the time of treatment decision as common in treatment 
trials (as opposed to the time of diagnosis of metastases in the original building and 
validation datasets) for Studies III–IV [40,119,130-132,139]. The patients were assigned 
to stages IVa, IVb, and IVc, originally corresponding to median predicted OSs of ≥12 
months, <12–6 months, and <6 months, respectively (online calculator available at http://
www.prognomics.org/huhwf.aspx). The ECOG performance status, LDLM, or AP level 
were missing for 16 patients in Study III and for 12 patients in Study IV, thus preventing 
calculation; however, the WF stage was assignable for 13 and nine patients, respectively, by 
using the prognostic table published with the building dataset [40]. In both Studies III and 
IV, three patients were not stageable. 
I provide two historical control survival curves to be used for comparing observed OS 
data from a new trial: one curve of the pooled data on 78 articles with 2,494 patients from 
Study I (for active treatment in doi: 10.5281/zenodo.1490563) and one curve of data on 108 
patients from Study III (for BSC in doi: 10.5281/zenodo.3369090). 
I constructed the historical control OS distribution for a phase II trial using as an example a 
large cutaneous melanoma study that included data from 1,200 patients [240]. 
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No. 338 consecutive patients
whose primary uveal melanoma was
managed in Helsinki University Hospital
and metastases were detected between
January 1999 and December 2016
Excluded
No. 1 treated with interferon as adjuvant before metastases
No. 5 all documents regarding treatment destroyed
No. 2 additional patients; neither categorizable as BSC nor
actively treated
No. 1 palliative radiation and palliative surgical
resection of an extrahepatic metastasis
No. 1 palliative radiation, then decision to treat









No. 2 diagnosis in the autopsy 
No. 1 metastases not consistent with uveal melanoma
No. 3 progressive second cancer (thyroid, renal, breast cancer) 
Excluded
No. 2 all reports of the 
imagings destroyed
No. 58 no CT/MRI
No. 10 no US
No. 21 >60 days between 
US and CT/MRI
No. 26 first metastases in 





The historical control curve is given by
where
S0(t) is given for active treatment in doi: 10.5281/zenodo.1490563 and for BSC in doi: 
10.5281/zenodo.3369090. 
n is the number of patients in the phase II trial.
At the time of analysis of a new phase II trial, the survival curve of this trial based on n 
patients is compared with the historical survival curve [240]. Somewhat arbitrarily, the 
endpoint was chosen to be 1 year. If the P-value is <0.01, then the new drug could be 
pursued further.
Analysis was performed with Stata (version 15 and 16, Stata Corp., College Station, TX, 
USA). The significance was set at <0.05, and all P-values are two-tailed. I report the median 
with range and interquartile range (IQR) for continuous variables. 
In Study I, I compared individual studies on each treatment modality to evaluate 
heterogeneity, and I then compared studies within each treatment modality according to 
the agents used. Thereafter, I compared each treatment modality against CHT and, finally, 
first-line treatments, if possible.
In Study II, I used a non-parametric test for trend to compare continuous variables between 
ordered groups. The sensitivity of US for detecting metastases was then calculated. 
For Studies III and IV, the primary endpoint was OS from the date of treatment decision 
of metastatic disease to death, as is usual in clinical trials [130-132,139]. The secondary 
endpoint was OS from the date of diagnosis of metastases to death to allow for comparisons 
with the validation dataset of the OOG, because that definition was originally used when 
building and validating the staging by the OOG [119]. Study III used OOG data for 
comparisons (E. R. et al. partly unpublished results) whereas Study IV used BSC (i.e. Study 
III data) as the comparison basis. 
Time trends in OS were analysed in Studies I and IV.
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I estimated OS using the Kaplan-Meier product-limit method, reported the median OS with 
a 95% CI, and compared unordered and ordered categories with the log-rank test and test 
for trend, respectively. I also adjusted with Bonferroni correction for multiple comparisons.
In addition, I used Cox proportional hazards regression to probe whether additional 
prognostic factors identified from the literature might help to predict OS together with the 
WF stage. I allowed independent variables in models if P < 0.10, tested the assumption 
of proportional hazards using the scaled adjustment of Schoenfeld residuals [40,241], and 
compared models using the deviance test. 
Study I was a systematic literature review and meta-analysis, and no institutional review 
board approval was needed. Studies II–IV were approved by the institutional review board 
of the Head and Neck Centre of the Hospital District of Helsinki and Uusimaa, the National 
Institute for Health and Welfare, and the National Supervisory Authority for Welfare and 
Health, Finland. Informed consent for participation was not required by Finnish law 




The search identified 1,663 publications on metastatic uveal melanoma and 78 of them 
contained original data digitisable for a pooled Kaplan-Meier graph, resulting in an analysis 
of 2,494 patients. The patients were categorisable to 13 treatment modalities (Table 29; Table 
1 in Study I). The median OS was 13 months (95% CI, 12–14) for the entire cohort, and the 
cumulative proportion of surviving patients declined rapidly from 52% at 12 months, to 
25% at 24 months, and 13% at 36 months. 
The OSs of CIT, HIA, TACE, PKI, and SIRT were comparable with CHT (P = 0.13–0.80; 
Figure 2 in Study I). Surgery, IHP, and IE were associated with longer OSs (P < 0.001, P 
= 0.004, and P = 0.008, respectively), whereas CPI was associated with a shorter OS than 
CHT (P < 0.001). 
However, upon closer analysis, only approximately 8% of treatments with CPI were first-line 
treatments. IE might not be generalisable as superior because the data were solely derived 
from a single-centre phase I and a subsequent phase II trial with a total of 59 patients. 
Moreover, the OS benefit of IHP depended entirely on one study with an exceptionally long 
OS [211]. 
The analysis could not be limited only to first-line treatments, because such patient-level 
data were available solely for CHT, CIT, HIA, and TACE. In addition, the WF staging was 
reported in 4% of the studies and 2% of the patients and could not be used for analysis. The 
interval from diagnosis of metastases to the initiation of study treatment also varied widely, 
and no more than 18% of the studies diligently reported all the components of OS from 
diagnosis of metastases to death or censoring. 
The trend in OS over the past four decades has exhibited no improvement (log-rank test for 
trend, P = 0.66). The 2,494 patients were included in the historical benchmark published in 














































































































































































































































































































































































































































































































































































































































































































































Of the 324 patients eligible for studies analysing treatment, 49% were female (Table 30). Of 
the primary uveal melanomas, 8% were categorised as small (T1), 38% medium-sized (T2), 
45% large (T3), and 9% very large (T4), and 45% extended from the choroid to the ciliary 
body or extraocularly. 
The median DMFI was 28 months (range, 0–265; IQR, 13–52). The follow-up for metastases 
was regular for 97% of the patients. Asymptomatic at the time of detection of metastases 
were 64% of them; 41% of those who received BSC and 76% of the patients who received 
active treatment, respectively. 
At the time of treatment decision, 93% of the patients had liver metastases with or without 
other sites. The median LDLM was 30 mm (range, 2–270), and categorised according to 
TNM, it was M1a in 48%, M1b in 31%, and M1c in 12% of the patients.
The AP exceeded the UNL in 38% of the 313 patients whose AP was available, and the 
ECOG performance status was 0–1 for 67%, 2 for 12%, and 3–4 for 20% of the patients. For 
patients who received BSC and active treatment, the ECOG performance status was 0–1 for 
32% and 83%, 2 for 12% and 11%, and 3–4 for 51% and 4%, respectively. According to the 
WF, 52%, 18%, and 28% were assigned to stages IVa, IVb, and IVc, respectively (Figure 2). 
The median interval from diagnosis of metastases to treatment decision was 29 days (range, 
0–758; IQR, 7.5–63) in the BSC dataset and 56 days (range, 0–1,059; IQR, 34–92) in actively 
treated patients (if more than 90 days, see Table 31 for reasons; E. R. et al. unpublished 
results). 
The median age at treatment decision was 68 years (range, 21–95), with one of the BSC 
patients and 14 of the actively treated patients being alive at the end of the follow-up. 
The audited COD was metastatic uveal melanoma for all others. The follow-up time was 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. The WF stage according to active treatment or BSC.
Table 31. Reasons for a delay of more than 90 days from diagnosis of metastasis to treatment 
decision for patients who received BSC or active treatment. E. R. et al. unpublished results.
Reason Active 
n = 59 (%)
BSC 
n = 17 (%)
Both 
n = 76 (%)
Initially negative FNAB or CNB result 21 (36) 4 (24) 25 (33)
Unfavourable performance status 0 (0) 3 (18) 3 (4)
Patient preference 2 (3) 2 (12) 4 (5)
Administrative reasons 1a (2) 1b (6) 2 (3)
Considered for SIRT but eventually not eligible 1 (2) 2 (12) 3 (4)
Other 0 (0) 1c (6) 1 (1)
Not specified 34 (58) 4 (24) 38 (50)
a Waiting for a trial opening. 
b The US report was mistakenly not read by the managing physician. 
c The managing oncologist decided that because of simultaneous prostate adenocarcinoma, no active 
treatment is indicated.
Altogether, 215 patients with liver metastases were included in the analysis, with 215 US, 
167 CT, and 69 MRI examinations. The first imaging modality was US for 91% of patients, 
CT for 8%, and MRI for 1%. The median interval from the first to the second imaging 



























US detected metastases in 95% of the patients, and it was consistent regarding the presence 
of metastases with CT and MRI in 89% of patients but showed quantitatively less metastases 
in 56% and more in 12% of them. US was inconsistent with CT/MRI in 23 patients (11%) 
(Figure 3). In nine patients, US detected metastases that were left undetected by CT for 
various reasons, and in another nine patients, US failed to suggest metastases. Among the 
latter nine patients, a newly detected lesion was present in US in seven patients, and LFTs 
were elevated in five patients. If a newly detected lesion in US or an elevated LFT was an 
indication to follow-up MRI, metastases would not have remained undetected in any of the 
nine patients.
The sensitivity of US against CT/MRI for findings that raised suspicion of metastases was 
96% (95% CI, 92–98); 215 US scans were true-positives, and 10 were false-negatives.
In 215 patients, MRI detected more metastases than US in 54% of scans and less in 3%. In 
comparison, CT detected more metastases than US in 31% and less in 16% of scans. When 
both MRI and CT were done, as was the case for 18 patients, then MRI detected more 
metastases than CT in 33% and less in 6% (Figure 4). The median OS from diagnosis of 
metastases was 12 months (range, 0–166).
Figure 3. Flow chart that shows patients whose US was inconsistent with CT/MRI. Reproduced 
by CC-BY-4.0 from [242].
Results
No. 23 Discrepancy of the presence of hepatic metastases between US 
and CT and/or MRI
No. 2 Equivocal finding and no further
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Figure 4. Number of reported metastases in CT compared to MRI. Reproduced by CC-BY-4.0 
from [242].
Of the 108 eligible patients, 24%, 19%, and 55% represented stages IVa, IVb, and IVc, 
respectively (Figure 2, Figure 5). The median OS was 1.6 months from the BSC decision for 
the entire cohort, and the 1-, 2-, and 3-year survival rate was 17%, 8%, and 5%, respectively. 
The median OS shortened with an increasing stage and was 12 (95% CI, 9.4–21) for stage 
IVa, 5.7 (95% CI, 0.7–11) for stage IVb, and 0.6 months (95% CI, 0.3–0.9) for stage IVc (P < 
0.001, log-rank test for trend). In stage IVa, 50% of patients survived ≥12 months, whereas 
in stage IVb, 50% survived ≥6 months and 25% ≥12 months. Meanwhile, in stage IVc, 97% 
died within 6 months. 
The weighted kappa for agreement between the observed and predicted OS categories 
was 0.614 and 0.615 (agreement 84% versus 59% expected, P < 0.001 and 83% versus 57% 
expected, P < 0.001, Figure 6), calculated from the treatment decision and diagnosis of 
metastases, respectively.
Regarding comparison to those patients who received systemic, non-surgical treatment 
in the OOG validation dataset (described in Chapter 2.4.2 Helsinki University 
Working Formulation), the OS for stages IVa and IVb was comparable to that after BSC 




Figure 5. Kaplan-Meier graph of overall OS from the date of diagnosis of metastasis to 
death for patients who received BSC and for patients from the OOG validation dataset who 
received systemic, non-surgical treatment [8], according to the WF stage. E. R. et al. 
unpublished results.
Of the 216 eligible patients, 66%, 17%, and 15% represented stages IVa, IVb, and IVc, 
respectively (Figure 2). The median OS was 12 months (95% CI, 11–14; range, 0.2–162) 
from the treatment decision of metastasis for the entire cohort, and the 6-, 12-, 24-, and 
36-month survival rates were 73%, 52%, 24%, and 13%, respectively. The median OS
shortened with an increasing stage and was 18 months (95% CI, 16–21) for stage IVa, 6.9
months (95% CI, 4.8–9.7) for stage IVb, and 1.9 months (95% CI, 1.6–2.9) for stage IVc
(P < 0.001, log-rank test for trend). In stage IVa, 73% of patients survived ≥12 months,
whereas in stage IVb, 57% survived ≥6 months and 19% ≥12 months, and in stage IVc, 88%
died within 6 months.
The weighted kappa for agreement between the observed and predicted OS categories 
was 0.549 and 0.603 (agreement 81% versus 58% expected, P < 0.001 and 85% versus 62% 




Of the 216 patients, 104 (48%) received first-line CIT, 43 (20%) CHT, 19 (9%) surgery, 22 
(10%) SIRT, 14 (6%) IFN/IL monotherapy, 8 (4%) CPI, 3 (1%) TACE, 2 (1%) other liver-
directed therapies, and 1 PKI (Table 29). Moreover, out of 104 patients who received CIT, 
48 (46%) received the traditional (in Finland) combination of bleomycin, vincristine, 
lomustine, and dacarbazine (BOLD) with IFN [107,126,147]. 
Only 12 (6%) of patients participated in four treatment trials (NCT02599402, 
NCT01974752, NCT00154388, and NCT00308607). 
The median OS with CIT in stage IVa was 18 months (95% CI, 15–21). The OS was longer 
in stage IVa for patients who received CIT (P = 0.013, with Bonferroni correction for three 
comparisons), but not in stages IVb and IVc, compared to CHT (Figure 7). 
Considering local treatments, the median OS of surgery was 27 months (95% CI, 17–73) in 
stage IVa; only one patient each was assigned to stage IVb and IVc. Surgery was associated 
with a longer OS in stage IVa than SIRT (P = 0.010, Bonferroni correction). No difference 
in OS was observed between CIT and SIRT (P > 0.99, Bonferroni correction) (Figure 7). 
Using BSC as a reference, OS after SIRT was comparable with BSC (P = 0.58, Bonferroni 
correction), and OS after CIT was comparable to BSC in stages IVa and IVb, and it was 
slightly longer (1.9 versus 0.6 months) in stage IVc (P = 0.003, Bonferroni correction).
To determine whether the treatment outcome has improved over time, I compared the 
time periods 1999–2010 (124 patients), and 2011–2016 (92 patients), and I observed no 
improvement in survival (P = 0.81, log-rank test; E. R. et al. unpublished results). 
By univariable Cox regression, the WF expectedly predicted a shorter OS [119]. Regarding 
components of the WF, a higher AP level, larger LDLM (by M1 category), and poorer 
ECOG performance status were associated with a shorter OS (P < 0.001 for each). Gender, 
age, DMFI, and the site of initial metastases were not associated with OS (P = 0.15–0.70, 
Cox regression). The presence of symptoms from metastases and LDH >2.0 x the 
UNL emerged as candidates for further modelling (P = 0.003 and P < 0.001, respectively). 
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Figure 6. Scatterplot of the predicted median OS time against the observed OS by the WF 
for patients who (A) received BSC (Study III) and (B) received active treatment. 
Time from beginning of treatment (months) 
Number at risk
70 65 52 33 23 15 10 7 7 5 3
17 9 1 0 0 0 0 0 0 0 0
14 3 1 0 0 0 0 0 0 0 0
19 12 8 4 3 2 1 1 0 0 0






CHT IVc 15 2 0 0 0 0 0 0 0 0 0
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Time from beginning of treatment (months) Number at risk
26 23 13 11 6 4 4 3 3 2 2
20 10 5 4 3 2 1 0 0 0 0
59 2 0 0 0 0 0 0 0 0 0
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Figure 7. Kaplan-Meier graph of OS from treatment decision to death staged with the WF for 
(A) CIT against CHT, (B) CIT against SIRT if only liver metastases, (C) BSC against CIT, and




In my meta-analysis (Study I), the median OS was 13 months for all 2,494 patients and 
essentially identical to my nationwide cohort (Studies II–IV) (Figure 8). Of the treatment 
modalities with >100 patients in Study I, surgery and IHP had a 5–6-month longer OS, 
and CPI had a 4-month shorter OS than CHT, for which the median OS was 11 months. 
These survival differences might disappear, as discussed below, if selection and lead time 
bias could be eliminated and if the analysis could be limited to first-line treatments, but 
patient-level data on first-line treatment analyses were available only for CHT, CIT, HIA, 
and TACE. 
To my knowledge, this review and meta-analysis was the first to summarise unrestricted 
patient-level data for treatment of metastatic uveal melanoma extracted from survival 
graphs. A review with 841 patients from 40 studies with metastatic uveal melanoma 
previously reported an objective response rate but did not analyse OS, and 70% of the 
articles in my meta-analysis were not included [243]. Another review tabulated the median 
OS from 36 articles but did not pool data [110]. 
After my meta-analysis was published, the International Rare Cancers Initiative reported a 
meta-analysis with individual patient variables and survival outcomes from 29 phase Ib/III 
trials in metastatic uveal melanoma from 2000 to 2016 [106]. They collected original study 
data of all treated patients directly from the trial investigators. It therefore follows that 
compared with the International Rare Cancers Initiative meta-analysis, mine did not include 
six studies because of missing patient-level OS data [244-249] and one study because of OS 
data inseparable between uveal and cutaneous melanoma [250]. Moreover, OS data were 
available for 912 patients, compared to 2,494 patients in my meta-analysis; the International 
Rare Cancers Initiative’s median OS was 10 months, compared with 13 months in my meta-
analysis; and the PFS was 3.3 months. The 6-month PFS rates and the 1-year OS rates for 
each treatment group were plotted against the group sample size. The International Rare 
Cancers Initiative suggested that liver-directed treatments provide longer PFS and OS than 
immunotherapy, anti-angiogenic agents, kinases, and chemotherapy; however, neither the 
line of therapy nor the impact of imaging or early diagnosis of metastases was evaluated. 
The International Rare Cancers Initiative also carried out univariable and multivariable 
analyses that I could not perform because my analysis was based on published records in 
which patient-level prognostic data were not presented. 
Regarding the treatment modalities with a significantly longer OS, IHP is even now offered 
only in selected centres, and one of those centres was responsible for the OS benefit in the 
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subanalysis and also reported lower mortality with its refined technique for IHP than what 
was the case earlier [211,212]. Systemic chemotherapy is frequently pursued in patients 
with heavy tumour burden, whereas patients who receive IHP more often have metastases 
limited to the liver. 
The median OS with surgery was 17 months, including some long-term survivors [184] 
(Study I). The surgically treated patients were overrepresented among those long-term 
survivors in my national cohort (Study IV), paralleling previous findings [37,41,109]. 
Unfortunately, few patients are eligible for surgery because most patients have widespread 
metastases [11].
Of the patients treated with CPI, only 8% received it as their first-line treatment, likely 
leading to a biased result (Study I). After my meta-analysis, the OSs for 133 patients who 
received various CPIs as their first-line treatment have been published in three papers, and 
the median OS in them ranged from 10 to 20 months [85,133,168]. Only eight patients 
received first-line CPI in my national cohort (Study IV; Table 29). Patients with loss-of-
function mutation in MBD4 are likely to benefit from CPI. The loss-of-function allele 
frequency in MBD4 among patients with uveal melanoma has been suggested to be 1%; 
however, in a recent Finnish series of 440 patients with uveal melanoma, no loss-of-
function variants were identified [32,33,251,252]. 
My meta-analysis provides clinicians with a rough comparison of the treatment options for 
metastatic uveal melanoma and supports earlier assumptions that no clinically significant 
improvement in OS exists, regardless of the mode of treatment. Much, if not most, of 
the perceived differences in survival between individual studies are likely attributable to 
surveillance, selection, and publication bias rather than treatment-related prolongation in 
OS. 
Based on my experience in extracting data for this meta-analysis, I also suggest guidelines 
for reporting a trial on treatment for metastatic uveal melanoma (Supplemental Digital 
Content 5 in Study I). The benchmark data published as open-access data, based on this 
study and including the data of 2,494 patients, are to be used for comparing observed OS 
data from a new single-arm, early phase trial.
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Figure 8. Kaplan-Meier graph of OS after metastatic uveal melanoma for actively treated 
patients from the nationwide cohort (Study IV) compared against meta-analysis (Study I). 
P-value is calculated using the log-rank test. 
In my national cohort, the ECOG performance status was missing for 2% of patients, AP 
for 11%, and LDLM for 9%. I was able to assign a stage for 98% of the patients, and the 
treatment modality was known for all eligible patients. 
In the International Rare Cancers Initiative meta-analysis with data requested directly 
from the investigators [106], 21% of the 912 patients lacked information on their 
ECOG performance status, 35% on AP, 35% on LDLM, and 19% on the line of therapy. 
Furthermore, in the only nationwide study prior to my study, 36% of the Dutch patients 
who received local therapy lacked an ECOG performance status, and neither the staging 
nor median OS was reported [86]. Meanwhile, in the largest single-institution report, 
the information regarding specific treatments was available only for 30% of patients [83]. 
Finally, only three studies reported staging at all [107,126,127]. 
METASTASES
Our population-based study of the agreement of hepatic US with staging CT/MRI revealed 
that US can be used in detecting metastases in patients with primary uveal melanoma in 
a real-life setting. The sensitivity of US in detecting metastases was 96%—US detected 
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metastases in 95% of the patients and agreed with a staging CT/MRI on their presence 
in 89% of patients, showing at least the same number of lesions as CT/MRI in 72% of the 
patients, and it detected metastases that CT initially missed for various reasons in nine 
patients. If US does not show metastases but any new lesion is detected, or if LFTs are newly 
elevated, then an MRI scan should be scheduled. Our findings suggest that a subsequent 
MRI is a more sensitive staging modality than CT in detecting hepatic metastases from 
uveal melanoma.
The sensitivity of US has been reported as 96–100%, in line with our study (Table 1) 
[14,72]. US and LFTs did not reveal hepatic metastases in four patients (2%), comparable to 
earlier published results (4%) [18]. However, in three of these patients, US detected a new 
lesion—although not specified as a suspected metastasis —that led to a confirmatory scan 
suggesting that in case of any newly-detected lesion, it should be considered a metastasis 
until proven otherwise [253]. Moreover, benign liver lesions, cysts, and hepatic steatosis are 
common at baseline, which must be taken into account during follow-up [9,10,14].
A review recommended that MRI should soon replace CT as the standard modality in liver 
imaging in uveal melanoma [22], and my study provides evidence that MRI outperforms 
CT in staging. MRI with a contrast agent is the most specific modality, and with a sensitivity 
of 67–100% and a specificity of 80–99% (Table 1), it is at least as sensitive as CT [13,17,74]. 
Additionally, the use of CT as a follow-up imaging method is limited by the fact that it uses 
ionizing radiation, while the utility of MRI might be limited by expense. Only a rough cost 
analysis was included in our study because of global differences in reimbursement systems. 
In North America, many centres prefer CT to US and MRI—a practice based partly on 
insurance policies that might possibly change based on my results and others that support 
MRI [22]. 
A single-centre study compared the survival of 90 patients diagnosed as having metastatic 
uveal melanoma before the onset of symptoms with annual LFTs, and of 259 patients after 
the onset of symptoms. The median time from diagnosis of primary uveal melanoma to 
death was similar to my study: 45 versus 45 months (Figure 9, schematic representation) 
[49]. A single-centre cohort study with 30 patients evaluating the utility of US for liver 
metastases reported that the median time from diagnosis of primary uveal melanoma to 
death was 36 months (Figure 9) [14]. Whether the difference in survival between the studies 
is dependent on the lead time bias, given the treatment or a different case mix, is impossible 
to assess. A similar surveillance strategy and staging would facilitate this comparison. 
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Figure 9. Schematic representation of survival of uveal melanoma patients with surveillance 
(Choudhary et al. [14] with 30 patients and Kim et al. with 90 patients [49]) and without 
surveillance (Kim et al. [49] with 259 patients) (E. R. et al. unpublished figure). 
The WF that was previously validated almost exclusively for actively treated patients also 
differentiates by OS patients receiving only BSC. In the validation dataset of the OOG, 11 
patients received BSC [119]. More importantly, the median OS for both stages IVa and IVb 
was comparable to that of systemically treated patients in the validation dataset. 
In our national cohort, 33% of the patients received BSC, which is comparable to 39% 
reported in the national cohort from the Netherlands—the sole nationwide study prior to 
my report [86]. Notably, these real-life percentages are comparable to recent studies from 
tertiary referral centres [83,85], although one might have hypothesised that active treatment 
would have been preferred in them and that patients with less favourable performance 
status would not have been referred to the tertiary centres by the managing physicians in 
the first place (Table 31). 
I present the third largest cohort of patients who received BSC for metastatic uveal 
melanoma [11,83] and the first one to stage them. Three studies with 11 [37], 23 [103], 
and 69 patients [86] reported prognostic factors for patients who received BSC (Table 28). 
Paralleling these studies, the patients in my series were older and had a poorer ECOG 
performance status [86,103] than actively treated patients; however, I cannot confirm 
that they had a shorter follow-up [37] or more elevated LDH [86]. The components of the 
WF—ECOG performance status, AP level, and LDLM—were also expectedly significant 
predictors of OS in my BSC cohort.
Of patients who received BSC, 24%, 19%, and 55% were assigned to WF stages IVa, IVb, 
and IVc, respectively, as opposed to 44%, 44%, and 15% of the patients receiving active 
treatment in the OOG validation dataset and 66%, 17%, and 15% of the actively treated 
patients in my national cohort (Study IV). The migration towards stage IVc in the BSC 
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dataset represents their poorer ECOG performance status because 44% of the BSC patients 
versus 99% of the actively treated ones presented a performance status of 0–2. This also 
reflects the fact that most treatment trials require a performance status of 0–1 [227], and 
in the few trials that reported the WF stage, it was stage IVa in 46% [107], 50% [126], and 
100% [127] of the patients.
Expectedly, the median OS was appreciably shorter (1.6 months), in aggregate, for patients 
who received BSC, compared to 13 months for the actively treated patients in the meta-
analysis (Study I) and 12 months for the actively treated patients in my national cohort 
(Study IV). The OS has repeatedly been claimed, or at least assumed, to be longer with 
active treatment as compared to BSC [7,11,37,83,85]; only rarely, the difference has been 
suggested to be related to patient characteristics rather than to a treatment effect [103,110]. 
Nevertheless, if staged, the median OS with BSC and active treatment appeared to be 
comparable for stages IVa and IVb. The stages IVa and IVb, included the majority (94%) 
of the patients whose ECOG performance status was 0–1. In stage IVc, OS was longer 
for actively treated patients. For this stage, a survival benefit can neither be rejected nor 
be confirmed because a probable bias was found: 85% of the patients had an ECOG 
performance status of 3–4 and hence were normally ineligible for active treatment. 
According to my study, using a validated staging system and a proper control group, 
especially in retrospective analyses and in non-randomised one-arm trials (e.g. the data 
that I published in an open-access data repository), is of paramount importance when 
analysing the results in an informative way. Indeed, it is likely that most trials continue to 
be non-randomised, given the relative rarity of metastatic uveal melanoma. 
In stage IVa, patients who received CIT or local therapy as their first-line treatment—
especially surgical resection—had a longer OS than patients who received CHT in my 
nationwide cohort. However, compared to BSC, the outcome after CIT was comparable, 
and survival after SIRT was also comparable to that after CIT and BSC. Consequently, I 
did not observe any convincing difference in OS in any comparison in patients whose WF 
stage was IVb or IVc. CHT might not have been the best reference group against which to 
compare other treatments, unlike what has repeatedly been done [24,25,51,134,135]. 
Due to encouraging pilot reports [147,254], the prospective EORTC multicentre study in 
2003 analysed the efficacy of BOLD chemotherapy plus recombinant IFN alpha-2b, which 
is a form of CIT, but did not confirm its efficacy [107], nor did the pooled survival data 
from five CIT studies confirm any difference between CHT and CIT (P = 0.80; Study I). 
However, as mentioned, in my national cohort, OS with CIT was longer than with CHT in 
stage IVa (P = 0.013; Study IV), but this difference resulted from a shorter OS with CHT. I 
could not find any possible bias by comparing the prognostic factors of patients assigned to 
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stage IVa who received CIT or CHT: 97% versus 95% had ECOG performance status 0–1; 
77% versus 74% had solely liver metastases; 61% versus 79% were from the M1a category 
(median LDLM 30 mm [range, 9–160; IQR, 20–50] versus 26 mm [range, 9–182; IQR, 
15–56]); and 77% versus 78% had elevated LDH, respectively. Analysis of the prognostic 
factors of patients assigned to stage IVa who received CHT or BSC revealed mainly that 
patients with CHT had more frequently elevated LDH: 95% versus 96% had ECOG 
performance status 0–1; 74% versus 73% had solely liver metastases; 79% versus 85% were 
from the M1a category; and 78% versus 54% had elevated LDH, respectively.
Local treatment for metastatic uveal melanoma limited to the liver has been suggested to 
prolong survival, based on a median OS of 18–35 months in non-controlled series [36-
38,84]. The presumably longer survival has been assumed to be secondary to better overall 
functional status [37], and I did not confirm the prolonged survival if stratified by stage. 
Lately, in Finland, SIRT has become the preferred first-line local treatment for metastatic 
uveal melanoma restricted to the liver in patients for whom surgical resection is unfeasible 
because of the number or distribution of metastases [51]. However, the present results 
suggest that as a first-line treatment, SIRT may not be superior to previously predominating 
CIT or, indeed, BSC, when considering stage-specific OS. 
Of note, only 12% of the actively treated patients in my cohort participated in a clinical 
trial, compared to 50% of patients in the nationwide study from the Netherlands [86]. 
Some national guidelines state that patients with metastatic uveal melanoma should be 
considered for clinical trials wherever possible and be informed of available trial options at 
other centres [57,58,60]. Likewise, in the Finnish cohort, only 9% of patients received local 
first-line treatment, compared to the 22% in the Netherlands, reflecting national differences 
in choosing first-line treatments.
The agreement between the WF-predicted and observed OS according to weighted kappa 
was actually stronger in my BSC (0.615) and the active treatment dataset (0.603) than in the 
validation dataset of the OOG (0.388) [119]. 
In the multivariable analysis stratified by stage, LDH improved the model fit, as has been 
proposed [21,111]. Although the LDH level was available only for a subpopulation of my 
patients, the data suggest that the WF staging might benefit from considering an elevation 
in LDH >2.5 x the UNL in addition to AP levels. 
To determine whether OS had improved over time, I compared the periods 1999–2010 and 
2011–2016, corresponding to the marketing authorisation of ipilimumab throughout the 
European Union in 2011 and equalling a recent single-centre study analysing OS before 
and after the introduction of CPI [37]. Unfortunately, my results from the meta-analysis 
(Study I) and national cohort (Study IV) both confirm that the survival outcome has not 
improved over time [37,83,139]. A single-centre study with 730 patients suggests that the 
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median OS was shortest for patients who were treated between 1971 and 1993, and it is 
similar in cohorts who were treated between 1998 and 2007 and between 2008 and 2017 
[84]. The latter two cohorts parallel my study period and results.
In Study I, the major limitation was the heterogeneity of the study populations. Most of 
the studies were retrospective, were small in sample size, and had different surveillance 
strategies, if any. The treatment was sometimes administered to treatment-naïve patients, 
sometimes as salvage therapy. To control for bias, I reported the percentage of first-line 
treatments and whether prior surgical resection was performed. Other causes of bias, 
such as variable ECOG performance status, sites and size of metastases, and LFTs were 
reported highly inconsistently and not at patient-level, and this unavoidably adds to the 
bias when combining data. Differences in methods between the original publications posed 
an additional challenge: the method by which the median OS was calculated was not always 
reported, and at-risk tables and censored observations were often missing from Kaplan-
Meier graphs. 
The limitations in Studies II–IV include their retrospective nature, which shows in varying 
imaging protocols (Study II) and in the variability in the selection of patients for treatments 
(Studies III and IV). The lag between the diagnosis of metastases and the treatment 
decision was >90 days in 28% of the actively treated patients, possibly further confounding 
the results. The geographically long distances in Finland make the follow-up for metastases 
and their treatment solely in the tertiary-centre challenging. The lack of information on 
genetic prognosticators is an additional limitation. However, these genetic prognosticators 
had not yet been identified and defined for most of the study period. 
In Study II, the maximum interval of 60 days between the US and CT/MRI scans may have 
biased the comparison of the imaging modalities because the doubling time of untreated 
metastases has a median of 63 days [16]. Nonetheless, in my study, the median observed 
interval was 17 days (IQR, 8–27), and this bias should favour CT/MRI rather than US.
Given the rarity of uveal melanoma, it is difficult to conduct randomised controlled trials. 
Therefore, multicentre studies—both prospective and retrospective—will be of great 
value, and the progress of digitalisation will aid in the integration of registries for research 
purposes so as to extract and aggregate data from electronic medical records or ‘data lakes’. 
To improve comparability, the establishment of a globally applicable follow-up strategy 
would be important. The imaging method used for review should be chosen based 
on sensitivity, specificity, availability, expenses, radiation exposure, and population 
characteristics. Considering the present results, a study comparing US and MRI head-to-
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head as a follow-up tool in high-risk patients with a cost-benefit analysis based on stage-
specific OS outcomes would be a logical follow-up to move international surveillance 
guidelines forward.
Furthermore, based on the summary of the delays of more than 90 days between the 
suspicion of metastases and the treatment decision (Table 31), further analysis is required 
in Finland to determine whether the delay shortens OS as well as how to reduce the delay 
and improve national clinical processes.
In the past decade, a significant expansion of knowledge regarding cytogenetic and 
molecular genetic data on uveal melanoma has taken place that may help to identify genetic 
subsets of patients who could benefit from certain therapies. The first subset of patients 
who may benefit from currently existing immunomodulatory therapies has already been 
recognised: patients with germline or somatic loss-of-function MBD4 mutation [32,33,251]. 
With time, genetic data with the most reliable and cost-effective biomarkers could possibly 
also be implemented in the staging systems for metastatic uveal melanoma. 
As outlined in my study, it is crucial to use proper control groups and staging when 
interpreting the results of non-randomised studies. The WF is confirmed as a useful, 
validated device in evaluating trials, even in its present form; however, the data also suggest 




1. Patient-level data aggregated from peer-reviewed reports provide no convincing 
evidence of a longer median OS for patients with metastatic uveal melanoma by 
any reported treatment modality, except surgical resection, or by decade. Most of 
the differences in reported OS are likely attributable to surveillance, selection, and 
publication bias.
2. US is a sensitive imaging method for detecting new hepatic metastases in patients 
with primary uveal melanoma. If US does not reveal definite metastases but any new 
lesion is detected, or if LFTs are newly elevated, then an MRI scan of the liver should be 
scheduled. Continued use of US as a surveillance method is supported by these data; 
however, a head-to-head comparison with MRI would be valuable.
3. The Helsinki University Hospital WF differentiates by OS also patients receiving BSC. 
4. Analysis of the Finnish national cohort confirms that no current treatment available 
for most patients with metastatic uveal melanoma is likely to appreciably prolong OS. 
While surgical resection may be superior, it is available only for a minority of patients. 
5. Validated staging systems and proper control groups are crucial for correct 
interpretation of outcomes in non-randomised trials.
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